WO2023068226A1 - 抗cd37抗体-薬物コンジュゲート - Google Patents
抗cd37抗体-薬物コンジュゲート Download PDFInfo
- Publication number
- WO2023068226A1 WO2023068226A1 PCT/JP2022/038604 JP2022038604W WO2023068226A1 WO 2023068226 A1 WO2023068226 A1 WO 2023068226A1 JP 2022038604 W JP2022038604 W JP 2022038604W WO 2023068226 A1 WO2023068226 A1 WO 2023068226A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- amino acid
- acid sequence
- heavy chain
- seq
- Prior art date
Links
- 229940049595 antibody-drug conjugate Drugs 0.000 title claims abstract description 218
- 239000000611 antibody drug conjugate Substances 0.000 title claims abstract description 207
- 239000003814 drug Substances 0.000 claims abstract description 130
- 229940079593 drug Drugs 0.000 claims abstract description 117
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims abstract description 102
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims abstract description 96
- 238000000034 method Methods 0.000 claims abstract description 94
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 82
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 15
- 230000027455 binding Effects 0.000 claims description 94
- 150000001413 amino acids Chemical group 0.000 claims description 90
- 238000009739 binding Methods 0.000 claims description 89
- 125000005647 linker group Chemical group 0.000 claims description 53
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 37
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 37
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 37
- 235000001014 amino acid Nutrition 0.000 claims description 31
- 238000002360 preparation method Methods 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 21
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 19
- 201000003444 follicular lymphoma Diseases 0.000 claims description 18
- 239000000562 conjugate Substances 0.000 claims description 15
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 14
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 13
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 12
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 11
- 230000004048 modification Effects 0.000 claims description 11
- 238000012986 modification Methods 0.000 claims description 11
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 10
- 208000027190 Peripheral T-cell lymphomas Diseases 0.000 claims description 10
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 10
- 208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 claims description 10
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 10
- 238000012217 deletion Methods 0.000 claims description 10
- 230000037430 deletion Effects 0.000 claims description 10
- 208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 claims description 10
- 201000005962 mycosis fungoides Diseases 0.000 claims description 10
- 230000003647 oxidation Effects 0.000 claims description 10
- 238000007254 oxidation reaction Methods 0.000 claims description 10
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 10
- 229940125644 antibody drug Drugs 0.000 claims description 9
- 238000012545 processing Methods 0.000 claims description 9
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 8
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 8
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 8
- 230000002197 limbic effect Effects 0.000 claims description 8
- 239000002504 physiological saline solution Substances 0.000 claims description 8
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 7
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- 239000002246 antineoplastic agent Substances 0.000 claims description 7
- 229930182817 methionine Natural products 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 6
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims description 6
- 235000003704 aspartic acid Nutrition 0.000 claims description 6
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 6
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 6
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 230000004988 N-glycosylation Effects 0.000 claims description 5
- 230000004989 O-glycosylation Effects 0.000 claims description 5
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 5
- 230000006240 deamidation Effects 0.000 claims description 5
- 238000006317 isomerization reaction Methods 0.000 claims description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
- 238000002560 therapeutic procedure Methods 0.000 claims description 5
- PTUJJIPXBJJLLV-UHFFFAOYSA-N 2-[[2-[[2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(=O)NCC(=O)NC(C(=O)NCC(O)=O)CC1=CC=CC=C1 PTUJJIPXBJJLLV-UHFFFAOYSA-N 0.000 claims description 4
- 230000009435 amidation Effects 0.000 claims description 4
- 238000007112 amidation reaction Methods 0.000 claims description 4
- OBVVKJDJORDBCH-CZDIJEQGSA-N 2-aminoacetic acid (2S)-2-amino-3-phenylpropanoic acid Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 OBVVKJDJORDBCH-CZDIJEQGSA-N 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 42
- 230000000694 effects Effects 0.000 abstract description 40
- 210000004881 tumor cell Anatomy 0.000 abstract description 19
- 230000001225 therapeutic effect Effects 0.000 abstract description 10
- 210000003719 b-lymphocyte Anatomy 0.000 abstract description 7
- 125000003275 alpha amino acid group Chemical group 0.000 description 180
- 210000004027 cell Anatomy 0.000 description 116
- 241000282414 Homo sapiens Species 0.000 description 73
- 239000000243 solution Substances 0.000 description 72
- 108091007433 antigens Proteins 0.000 description 60
- 102000036639 antigens Human genes 0.000 description 59
- 239000000427 antigen Substances 0.000 description 54
- 239000012634 fragment Substances 0.000 description 45
- 108090000623 proteins and genes Proteins 0.000 description 45
- 239000002773 nucleotide Substances 0.000 description 42
- 125000003729 nucleotide group Chemical group 0.000 description 41
- 230000000259 anti-tumor effect Effects 0.000 description 38
- 150000001875 compounds Chemical class 0.000 description 34
- 239000007864 aqueous solution Substances 0.000 description 29
- 239000013604 expression vector Substances 0.000 description 27
- 108020004414 DNA Proteins 0.000 description 25
- 229940024606 amino acid Drugs 0.000 description 22
- 238000011579 SCID mouse model Methods 0.000 description 21
- 230000008033 biological extinction Effects 0.000 description 21
- 201000011510 cancer Diseases 0.000 description 20
- 235000018102 proteins Nutrition 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 19
- 239000000203 mixture Substances 0.000 description 19
- 239000000126 substance Substances 0.000 description 19
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 18
- 125000000539 amino acid group Chemical group 0.000 description 17
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 description 15
- 238000002835 absorbance Methods 0.000 description 15
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 13
- 238000000746 purification Methods 0.000 description 13
- 210000003462 vein Anatomy 0.000 description 13
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 239000000872 buffer Substances 0.000 description 11
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- 230000005917 in vivo anti-tumor Effects 0.000 description 10
- 229950009416 polatuzumab vedotin Drugs 0.000 description 10
- 239000011780 sodium chloride Substances 0.000 description 10
- 238000010276 construction Methods 0.000 description 9
- 239000013642 negative control Substances 0.000 description 9
- -1 RITUXAN® Substances 0.000 description 8
- 239000002299 complementary DNA Substances 0.000 description 8
- 230000021615 conjugation Effects 0.000 description 8
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 7
- 241000282412 Homo Species 0.000 description 7
- 238000012512 characterization method Methods 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000010367 cloning Methods 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 229950009429 exatecan Drugs 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 229960004641 rituximab Drugs 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 6
- 206010035226 Plasma cell myeloma Diseases 0.000 description 6
- 108010076504 Protein Sorting Signals Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 230000004071 biological effect Effects 0.000 description 6
- 239000007853 buffer solution Substances 0.000 description 6
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 6
- BEBCJVAWIBVWNZ-UHFFFAOYSA-N glycinamide Chemical compound NCC(N)=O BEBCJVAWIBVWNZ-UHFFFAOYSA-N 0.000 description 6
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 102000048426 human CD37 Human genes 0.000 description 6
- 210000004408 hybridoma Anatomy 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- 230000008685 targeting Effects 0.000 description 6
- 239000013598 vector Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 5
- 230000001472 cytotoxic effect Effects 0.000 description 5
- 238000010586 diagram Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 201000000050 myeloid neoplasm Diseases 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- JJAHTWIKCUJRDK-UHFFFAOYSA-N succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate Chemical compound C1CC(CN2C(C=CC2=O)=O)CCC1C(=O)ON1C(=O)CCC1=O JJAHTWIKCUJRDK-UHFFFAOYSA-N 0.000 description 5
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 4
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 4
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
- IEDXPSOJFSVCKU-HOKPPMCLSA-N [4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[6-(2,5-dioxopyrrolidin-1-yl)hexanoylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methyl N-[(2S)-1-[[(2S)-1-[[(3R,4S,5S)-1-[(2S)-2-[(1R,2R)-3-[[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl]-3-methoxy-5-methyl-1-oxoheptan-4-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-N-methylcarbamate Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C)[C@@H](O)c1ccccc1)OC)N(C)C(=O)[C@@H](NC(=O)[C@H](C(C)C)N(C)C(=O)OCc1ccc(NC(=O)[C@H](CCCNC(N)=O)NC(=O)[C@@H](NC(=O)CCCCCN2C(=O)CCC2=O)C(C)C)cc1)C(C)C IEDXPSOJFSVCKU-HOKPPMCLSA-N 0.000 description 4
- 239000000370 acceptor Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 230000001085 cytostatic effect Effects 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 231100000673 dose–response relationship Toxicity 0.000 description 4
- 238000004520 electroporation Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 229960005558 mertansine Drugs 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000000704 physical effect Effects 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- MFRNYXJJRJQHNW-DEMKXPNLSA-N (2s)-2-[[(2r,3r)-3-methoxy-3-[(2s)-1-[(3r,4s,5s)-3-methoxy-5-methyl-4-[methyl-[(2s)-3-methyl-2-[[(2s)-3-methyl-2-(methylamino)butanoyl]amino]butanoyl]amino]heptanoyl]pyrrolidin-2-yl]-2-methylpropanoyl]amino]-3-phenylpropanoic acid Chemical compound CN[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H]([C@@H](C)CC)[C@H](OC)CC(=O)N1CCC[C@H]1[C@H](OC)[C@@H](C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 MFRNYXJJRJQHNW-DEMKXPNLSA-N 0.000 description 3
- ZHSKUOZOLHMKEA-UHFFFAOYSA-N 4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydron;chloride Chemical compound Cl.ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 ZHSKUOZOLHMKEA-UHFFFAOYSA-N 0.000 description 3
- WXNSCLIZKHLNSG-MCZRLCSDSA-N 6-(2,5-dioxopyrrol-1-yl)-N-[2-[[2-[[(2S)-1-[[2-[[2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]amino]-2-oxoethoxy]methylamino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]hexanamide Chemical compound CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=C1N=C1C=C(F)C(C)=C4CC[C@H](NC(=O)COCNC(=O)CNC(=O)[C@H](CC5=CC=CC=C5)NC(=O)CNC(=O)CNC(=O)CCCCCN5C(=O)C=CC5=O)C3=C14)C2=O WXNSCLIZKHLNSG-MCZRLCSDSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 3
- 229920002873 Polyethylenimine Polymers 0.000 description 3
- 239000008351 acetate buffer Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 210000000628 antibody-producing cell Anatomy 0.000 description 3
- 229960001230 asparagine Drugs 0.000 description 3
- 235000009582 asparagine Nutrition 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 229960001507 ibrutinib Drugs 0.000 description 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 108010093470 monomethyl auristatin E Proteins 0.000 description 3
- 108010059074 monomethylauristatin F Proteins 0.000 description 3
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000001131 transforming effect Effects 0.000 description 3
- 108091005703 transmembrane proteins Proteins 0.000 description 3
- 102000035160 transmembrane proteins Human genes 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 description 3
- 229960001183 venetoclax Drugs 0.000 description 3
- GTBCXYYVWHFQRS-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)pentanoate Chemical compound C=1C=CC=NC=1SSC(C)CCC(=O)ON1C(=O)CCC1=O GTBCXYYVWHFQRS-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- DVVGIUUJYPYENY-UHFFFAOYSA-N 1-methylpyridin-2-one Chemical compound CN1C=CC=CC1=O DVVGIUUJYPYENY-UHFFFAOYSA-N 0.000 description 2
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 101100278318 Dictyostelium discoideum dohh-2 gene Proteins 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000043977 Tetraspanins Human genes 0.000 description 2
- 108700031126 Tetraspanins Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 101710120037 Toxin CcdB Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940018964 belantamab mafodotin Drugs 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- 229960000455 brentuximab vedotin Drugs 0.000 description 2
- HXCHCVDVKSCDHU-LULTVBGHSA-N calicheamicin Chemical group C1[C@H](OC)[C@@H](NCC)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@](C/3=C/CSSSC)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HXCHCVDVKSCDHU-LULTVBGHSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 238000000113 differential scanning calorimetry Methods 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000003917 human chromosome Anatomy 0.000 description 2
- 150000007857 hydrazones Chemical class 0.000 description 2
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000018358 immunoglobulin Human genes 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 108010082117 matrigel Proteins 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
- 229960003330 pentetic acid Drugs 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 229950000143 sacituzumab govitecan Drugs 0.000 description 2
- ULRUOUDIQPERIJ-PQURJYPBSA-N sacituzumab govitecan Chemical compound N([C@@H](CCCCN)C(=O)NC1=CC=C(C=C1)COC(=O)O[C@]1(CC)C(=O)OCC2=C1C=C1N(C2=O)CC2=C(C3=CC(O)=CC=C3N=C21)CC)C(=O)COCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N1)C=C1CNC(=O)C(CC1)CCC1CN1C(=O)CC(SC[C@H](N)C(O)=O)C1=O ULRUOUDIQPERIJ-PQURJYPBSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000008399 tap water Substances 0.000 description 2
- 235000020679 tap water Nutrition 0.000 description 2
- 150000003568 thioethers Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 229960001612 trastuzumab emtansine Drugs 0.000 description 2
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 description 1
- RWZVMMQNDHPRQD-SFTDATJTSA-N (6as)-3-[3-[[(6as)-2-methoxy-8-methylidene-11-oxo-7,9-dihydro-6ah-pyrrolo[2,1-c][1,4]benzodiazepin-3-yl]oxy]propoxy]-2-methoxy-8-methylidene-7,9-dihydro-6ah-pyrrolo[2,1-c][1,4]benzodiazepin-11-one Chemical compound N1=C[C@@H]2CC(=C)CN2C(=O)C(C=C2OC)=C1C=C2OCCCOC1=CC(N=C[C@H]2N(CC(=C)C2)C2=O)=C2C=C1OC RWZVMMQNDHPRQD-SFTDATJTSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- MEXZZLMLPPPMCH-UHFFFAOYSA-N 1-phenyl-n-(2-phenylethoxy)methanamine Chemical class C=1C=CC=CC=1CNOCCC1=CC=CC=C1 MEXZZLMLPPPMCH-UHFFFAOYSA-N 0.000 description 1
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 description 1
- SLMVEZKWNOGJPD-UHFFFAOYSA-N 4-(pyridin-2-yldisulfanyl)butanoic acid Chemical compound OC(=O)CCCSSC1=CC=CC=N1 SLMVEZKWNOGJPD-UHFFFAOYSA-N 0.000 description 1
- XPHFWNCBAPUQCG-UHFFFAOYSA-N 4-[[1-(2,5-dioxopyrrolidin-1-yl)-2h-pyridin-2-yl]disulfanyl]pentanoic acid Chemical compound OC(=O)CCC(C)SSC1C=CC=CN1N1C(=O)CCC1=O XPHFWNCBAPUQCG-UHFFFAOYSA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108010027164 Amanitins Proteins 0.000 description 1
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100038080 B-cell receptor CD22 Human genes 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 101150066967 CD37 gene Proteins 0.000 description 1
- 101100120609 Caenorhabditis elegans frh-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical class NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 101150023991 FMNL1 gene Proteins 0.000 description 1
- 101150005226 FRL1 gene Proteins 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical class F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 102100028930 Formin-like protein 1 Human genes 0.000 description 1
- 239000012739 FreeStyle 293 Expression medium Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 description 1
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 description 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 description 1
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000012515 MabSelect SuRe Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical class CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000007801 affinity label Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- CIORWBWIBBPXCG-JZTFPUPKSA-N amanitin Chemical compound O=C1N[C@@H](CC(N)=O)C(=O)N2CC(O)C[C@H]2C(=O)N[C@@H](C(C)[C@@H](O)CO)C(=O)N[C@@H](C2)C(=O)NCC(=O)N[C@@H](C(C)CC)C(=O)NCC(=O)N[C@H]1CS(=O)C1=C2C2=CC=C(O)C=C2N1 CIORWBWIBBPXCG-JZTFPUPKSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960003121 arginine Drugs 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical class C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229930195731 calicheamicin Natural products 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 238000012054 celltiter-glo Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 150000003946 cyclohexylamines Chemical class 0.000 description 1
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical class OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 150000005332 diethylamines Chemical class 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 229960005501 duocarmycin Drugs 0.000 description 1
- 229930184221 duocarmycin Natural products 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229950004930 enfortumab vedotin Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000011503 in vivo imaging Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- OHSVLFRHMCKCQY-NJFSPNSNSA-N lutetium-177 Chemical compound [177Lu] OHSVLFRHMCKCQY-NJFSPNSNSA-N 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- WKPWGQKGSOKKOO-RSFHAFMBSA-N maytansine Chemical class CO[C@@H]([C@@]1(O)C[C@](OC(=O)N1)([C@H]([C@@H]1O[C@@]1(C)[C@@H](OC(=O)[C@H](C)N(C)C(C)=O)CC(=O)N1C)C)[H])\C=C\C=C(C)\CC2=CC(OC)=C(Cl)C1=C2 WKPWGQKGSOKKOO-RSFHAFMBSA-N 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229950002138 naratuximab Drugs 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229950007318 ozogamicin Drugs 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 208000017426 precursor B-cell acute lymphoblastic leukemia Diseases 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 210000001948 pro-b lymphocyte Anatomy 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011403 purification operation Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- YUOCYTRGANSSRY-UHFFFAOYSA-N pyrrolo[2,3-i][1,2]benzodiazepine Chemical class C1=CN=NC2=C3C=CN=C3C=CC2=C1 YUOCYTRGANSSRY-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- UOWVMDUEMSNCAV-WYENRQIDSA-N rachelmycin Chemical compound C1([C@]23C[C@@H]2CN1C(=O)C=1NC=2C(OC)=C(O)C4=C(C=2C=1)CCN4C(=O)C1=CC=2C=4CCN(C=4C(O)=C(C=2N1)OC)C(N)=O)=CC(=O)C1=C3C(C)=CN1 UOWVMDUEMSNCAV-WYENRQIDSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- HNMATTJJEPZZMM-BPKVFSPJSA-N s-[(2r,3s,4s,6s)-6-[[(2r,3s,4s,5r,6r)-5-[(2s,4s,5s)-5-[acetyl(ethyl)amino]-4-methoxyoxan-2-yl]oxy-6-[[(2s,5z,9r,13e)-13-[2-[[4-[(2e)-2-[1-[4-(4-amino-4-oxobutoxy)phenyl]ethylidene]hydrazinyl]-2-methyl-4-oxobutan-2-yl]disulfanyl]ethylidene]-9-hydroxy-12-(m Chemical compound C1[C@H](OC)[C@@H](N(CC)C(C)=O)CO[C@H]1O[C@H]1[C@H](O[C@@H]2C\3=C(NC(=O)OC)C(=O)C[C@@](C/3=C/CSSC(C)(C)CC(=O)N\N=C(/C)C=3C=CC(OCCCC(N)=O)=CC=3)(O)C#C\C=C/C#C2)O[C@H](C)[C@@H](NO[C@@H]2O[C@H](C)[C@@H](SC(=O)C=3C(=C(OC)C(O[C@H]4[C@@H]([C@H](OC)[C@@H](O)[C@H](C)O4)O)=C(I)C=3C)OC)[C@@H](O)C2)[C@@H]1O HNMATTJJEPZZMM-BPKVFSPJSA-N 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- ZZORFUFYDOWNEF-UHFFFAOYSA-N sulfadimethoxine Chemical compound COC1=NC(OC)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 ZZORFUFYDOWNEF-UHFFFAOYSA-N 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- ATGUDZODTABURZ-UHFFFAOYSA-N thiolan-2-ylideneazanium;chloride Chemical compound Cl.N=C1CCCS1 ATGUDZODTABURZ-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 229940049679 trastuzumab deruxtecan Drugs 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 1
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 208000023747 urothelial carcinoma Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
Definitions
- the present invention relates to an anti-CD37 antibody that binds to CD37, a method for producing the antibody, an antibody-drug conjugate containing the antibody, an antitumor agent containing the antibody-drug conjugate, and the like.
- Cancer is a leading cause of death, and the number of cancer patients is expected to increase as the population ages, but the treatment needs are still not fully met.
- Conventional chemotherapeutic agents have side effects due to their low selectivity, which is toxic not only to tumor cells but also to normal cells. The problem is that it can't be done. For this reason, in recent years, the development of highly selective molecular-targeted drugs and antibody drugs that target specific molecules that are involved in the canceration of cells and molecules that show mutations characteristic of cancer cells or that are highly expressed have been promoted. It is
- Rituximab is an antibody drug that targets CD20, and was approved by the FDA in 1997 as a therapeutic agent for B-cell non-Hodgkin's lymphoma (NHL) (Non-Patent Document 1).
- the main modes of action of rituximab are direct apoptosis induction, ADCC (antibody-dependent cellular cytotoxicity), CDC (complement-dependent cytotoxicity), and target CD20-expressing diffuse large B-cell lymphoma. (DLBCL) and other B-cell NHL are shown to have dramatic therapeutic effects, and are still widely used today.
- Antibodies are highly stable in the blood and are expected to reduce side effects because they specifically bind to target antigens, and many antibody drugs have been developed against molecules that are highly expressed on the surface of cancer cells.
- Antibody-Drug Conjugate is one of the techniques utilizing the antigen-specific binding ability of antibodies.
- An ADC is an antibody that binds to an antigen expressed on the surface of cancer cells and that binds to an antibody capable of internalizing the antigen into cells through binding to a drug having cytotoxic activity.
- ADCs are expected to accumulate drugs in cancer cells and kill cancer cells by efficiently delivering drugs to cancer cells (Non-Patent Document 3, Patent Documents 1 and 2).
- a calicheamicin derivative is bound to a monoclonal antibody
- Mylotarg registered trademark
- (gemtuzumab ozogamicin) targeting CD33 is used as a therapeutic agent for acute myeloid leukemia
- Vesponsa registered trademark
- Inotuzumab ozogamicin
- ADCETRIS registered trademark
- Brentuximab vedotin which is a monoclonal antibody conjugated to monomethylauristatin E and targets CD30, has been approved as a therapeutic agent for Hodgkin's lymphoma and anaplastic large cell lymphoma.
- Kadcyla registered trademark
- trastuzumab emtansine which is an anti-HER2 monoclonal antibody conjugated with emtansine
- Conjugated Trodelvy® is used to treat advanced triple-negative breast cancer.
- target antigens suitable for ADCs as antitumor agents include specific high expression on the surface of cancer cells, low expression or no expression on normal cells, ability to internalize inside cells, For example, it is not secreted from the surface.
- Important features of antibodies suitable for ADCs include specific binding to target antigens and high internalization potential. Antibody internalization ability depends on the properties of both the target antigen and the antibody. It is difficult to speculate on highly potent antibodies. Therefore, obtaining an antibody with high internalization ability against a target antigen is an important issue in developing highly effective ADCs (Non-Patent Document 4).
- CD37 is a four-transmembrane protein of the tetraspanin superfamily (Non-Patent Document 5). According to previous studies, it has been reported that cell survival is regulated through activation of the PI3K/Akt pathway, or that CD37-deficient mice are analyzed to decrease IgG1 production. It is unknown (Non-Patent Documents 6 and 7). CD37 is widely expressed in differentiation stages from precursor B cells to mature B cells, but not in plasma cells. Expression is also observed in T cells, NK cells, and monocytes, but the expression level is low, and it is not expressed in blood cells such as erythrocytes and platelets.
- Non-Patent Document 8 B-cell non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), and such an expression profile is suggested to be a promising therapeutic target in B-cell malignant lymphoma.
- Non-Patent Document 8 several antibody drugs targeting CD37 have progressed to clinical trials.
- CD37 is considered to be a promising target for ADC because of its high internalization activity
- IMGN529 which is an anti-CD37 antibody conjugated with DM1
- IMGN529 showed efficacy only in certain patients, with an overall response rate of 12.8% in a Phase I trial targeting patients with relapsed/refractory B-cell non-Hodgkin's lymphoma (NHL) ( Non-Patent Document 10).
- CD37-targeted drugs Betalutin (Lutetium-177-labeled anti-CD37 antibody), GEN3009 (anti-CD37 biparatopic antibody), and CAR37 T cells (CD37-targeted CAR T cells) are currently undergoing clinical trials (non-patent References 11, 12, 13).
- Enhertz registered trademark
- HER3-DXd Non-Patent Document 15
- Trop2-DXd Non-Patent Document 16
- deruxtecan-bound ADCs Furthermore, there has been no report on a deruxtecan-binding ADC targeting B-cell non-Hodgkin's lymphoma.
- An object of the present invention is to provide an antibody that specifically binds to CD37-positive tumor cells such as B-cell malignant lymphoma, an antibody-drug conjugate containing the antibody, and a therapeutic effect on tumors using the antibody-drug conjugate. , a method for treating tumors using the pharmaceutical composition, a method for producing the antibody, a method for producing the antibody-drug conjugate, and the like.
- the present inventors have made intensive studies to achieve the above objects, and found that an anti-CD37 antibody-drug conjugate in which an anti-CD37 antibody is bound to an intracellularly toxic drug via a linker with a specific structure.
- the inventors have completed the present invention by discovering that it exerts an antitumor effect against CD37-positive malignant tumors such as B-cell malignant lymphoma. That is, the present invention includes the following inventions.
- GGFG indicates an amino acid sequence linked by peptide bonds consisting of glycine-glycine-phenylalanine-glycine, -(NH-DX) is represented by the following formula:
- the anti-CD37 antibody has 90% or more homology with the 21st to 128th amino acid sequence of the full-length light chain amino acid sequence shown in SEQ ID NO: 2 or the 21st to 128th amino acid sequence of the full-length light chain amino acid sequence shown in SEQ ID NO: 2. and the 20th to 138th amino acids of the heavy chain full-length amino acid sequence shown in SEQ ID NO: 4 or the 20th to 138th amino acids of the heavy chain full-length amino acid sequence shown in SEQ ID NO: 4
- An antibody comprising a heavy chain variable region having an amino acid sequence that is 90% or more homologous to the sequence.
- the anti-CD37 antibody is an antibody comprising the heavy chain variable region and the light chain variable region according to any one selected from the group consisting of the following (h) to (j) [1] or [2 ] antibody-drug conjugate of: (h) consisting of a light chain variable region consisting of the 21st to 128th amino acid sequence of the full length light chain amino acid sequence shown in SEQ ID NO: 2 and the 20th to 138th amino acid sequence of the full length heavy chain amino acid sequence shown in SEQ ID NO: 6 heavy chain variable region; (i) consisting of a light chain variable region consisting of the 21st to 128th amino acid sequence of the full length light chain amino acid sequence shown in SEQ ID NO: 2 and the 20th to 138th amino acid sequence of the full length heavy chain amino acid sequence shown in SEQ ID NO: 8; heavy chain variable region; and (j) a light chain variable region consisting of the 21st to 128th amino acid sequence of the full length light chain amino acid sequence shown in SEQ ID NO: 2
- the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain according to any one selected from the group consisting of (k) to (n) below or one antibody-drug conjugate: (k) a light chain consisting of the 21st to 234th amino acid sequences of the full-length light chain amino acid sequence shown in SEQ ID NO:2 and a heavy chain consisting of the 20th to 468th amino acid sequences of the full-length heavy chain amino acid sequence shown in SEQ ID NO:4 ; (l) A light chain consisting of the 21st to 234th amino acid sequences of the full-length light chain amino acid sequence shown in SEQ ID NO: 2 and a heavy chain consisting of the 20th to 468th amino acid sequences of the full-length heavy chain amino acid sequence shown in SEQ ID NO: 6 ; (m) a light chain consisting of the 21st to 234th amino acid sequences of the full-length light chain amino acid sequence shown in SEQ ID NO:
- the anti-CD37 antibody is an antibody comprising a heavy chain and a light chain according to any one selected from the group consisting of the following (l) to (n): or one antibody-drug conjugate:
- Antibody heavy chain undergoes N-linked glycosylation, O-linked glycosylation, amino-terminal processing, carboxyl-terminal processing, deamidation, aspartic acid isomerization, methionine oxidation, tryptophan oxidation, amino having undergone one or two or more modifications selected from the group consisting of addition of a methionine residue at the end, amidation of a proline residue, and deletion of one or two amino acids at the carboxyl terminus, [1] to [ 9]. [11] The antibody-drug conjugate of [10] wherein one or two amino acids are deleted at the carboxyl terminus of the antibody heavy chain.
- [12] The antibody-drug conjugate of [10] or [11] in which one amino acid is deleted at the carboxyl terminus of both of the two antibody heavy chains.
- [13] The antibody-drug conjugate of any one of [10] to [12], wherein the carboxyl-terminal proline residue of the antibody heavy chain is further amidated.
- [15] The antibody-drug conjugate of any one of [1] to [14], wherein the drug-linker structure has an average binding number of 2 to 8 per antibody.
- a pharmaceutical composition comprising the antibody-drug conjugate of any one of [1] to [18], a pharmacologically acceptable salt thereof, or a hydrate thereof.
- the pharmaceutical composition of [19] which is an antitumor drug.
- the pharmaceutical composition of [20], wherein the tumor is a CD37-expressing tumor is any one tumor selected from the group consisting of diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, limbic lymphoma, Burkitt's lymphoma and chronic lymphocytic leukemia.
- the tumor is any one selected from the group consisting of peripheral T-cell lymphoma, T-cell lymphoma such as cutaneous T-cell lymphoma, myelodysplastic syndrome and acute myelogenous leukemia, The pharmaceutical composition of [20] or [21].
- a method of treating a tumor comprising the step of administering the antibody-drug conjugate of any one of [1] to [18], a pharmacologically acceptable salt thereof, or a hydrate thereof to an individual. .
- the tumor is any one tumor selected from the group consisting of diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, limbic lymphoma, Burkitt's lymphoma and chronic lymphocytic leukemia.
- the tumor is any one selected from the group consisting of peripheral T-cell lymphoma, T-cell lymphoma such as cutaneous T-cell lymphoma, myelodysplastic syndrome and acute myelogenous leukemia, The therapeutic method of [24] or [25].
- a tumor therapeutic agent comprising the antibody-drug conjugate of any one of [1] to [18], a pharmacologically acceptable salt thereof, or a hydrate thereof.
- [30] The antibody-drug conjugate of any one of [1] to [18], a pharmacologically acceptable salt thereof, or a hydrate thereof for the preparation of a medicament for treating tumors use.
- the present invention also includes the following inventions.
- An antibody or a function of the antibody characterized by comprising a step of culturing the host cell according to (v) or (vi), and a step of collecting the antibody of interest from the culture obtained in said step A method for producing a sex fragment.
- (viii) An antibody or a functional fragment of the antibody, which is obtained by the production method described in (vii).
- the antibody of (viii) comprising one or more modifications selected from the group consisting of addition of a group, amidation of proline residues, and deletion of one or two amino acids at the carboxyl terminus, or the function of the antibody sex fragment.
- (xiv) a step of culturing the host cell according to (v) or (vi), a step of collecting the antibody of interest or a functional fragment of the antibody from the culture obtained in the step, and A method for producing an antibody-drug conjugate, comprising the step of reacting an antibody or a functional fragment of said antibody with a drug-linker intermediate compound.
- the anti-CD37 antibody of the present invention is characterized by specific binding to CD37-positive tumor cells such as B-cell malignant lymphoma.
- An anti-CD37 antibody-drug conjugate in which an intracellularly toxic drug is bound to the antibody via a linker of a specific structure, is administered to a patient having cancer cells expressing CD37, resulting in an excellent It can be expected to achieve antitumor efficacy and safety. That is, the anti-CD37 antibody-drug conjugate of the present invention is useful as an antitumor agent against B-cell malignant lymphoma and the like.
- the anti-CD37 antibody-drug conjugate of the present invention has a good recovery rate in physiological saline and can be handled in physiological saline.
- FIG. 1 shows the nucleotide sequence encoding the hmAb-L11 light chain and the amino acid sequence of the hmAb-L11 light chain.
- FIG. 1 shows the nucleotide sequence encoding the hmAb-H11 heavy chain and the amino acid sequence of the hmAb-H11 heavy chain.
- FIG. 1 shows the nucleotide sequence encoding hmAb-H541 heavy chain and the amino acid sequence of hmAb-H541 heavy chain.
- FIG. 1 shows the nucleotide sequence encoding hmAb-H551 heavy chain and the amino acid sequence of hmAb-H551 heavy chain.
- FIG. 10 is a diagram evaluating the binding of humanized anti-CD37 antibody-drug conjugates to the CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7.
- Figure 10 is a diagram evaluating the in vitro cytostatic activity of humanized anti-CD37 antibody-drug conjugates against the CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7.
- FIG. 4 shows the in vivo anti-tumor effects of humanized anti-CD37 antibody-drug conjugates on SCID mice engrafted with the CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7.
- FIG. 4 shows the in vivo anti-tumor effects of humanized anti-CD37 antibody-drug conjugates on SCID mice engrafted with the CD37-positive human diffuse large B-cell lymphoma cell line WSU-DLCL2.
- FIG. 4 shows the in vivo anti-tumor effects of humanized anti-CD37 antibody-drug conjugates on SCID mice engrafted with the CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8.
- Humanized anti-CD37 antibody-drug conjugates, POLIVY® and IMGN529 exhibit in vivo anti-tumor effects against SCID mice engrafted with the CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7. It is a diagram showing. Humanized anti-CD37 antibody-drug conjugates, POLIVY and IMGN529, demonstrated in vivo antitumor effects against SCID mice engrafted with the CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-8 It is a diagram.
- FIG. 4 shows the in vivo anti-tumor effects of humanized anti-CD37 antibody-drug conjugates on SCID mice engrafted with the CD37-positive human diffuse large B-cell lymphoma cell line SU-DHL-4.
- FIG. 2 shows the antitumor effect.
- FIG. 4 shows the in vivo anti-tumor effects of humanized anti-CD37 antibody-drug conjugates, POLIVY and IMGN529, on SCID mice engrafted with the CD37-positive human follicular lymphoma cell line DOHH-2.
- the term "gene” means a nucleic acid molecule containing a nucleotide sequence encoding an amino acid of a protein or a complementary strand thereof.
- Polynucleotides, oligonucleotides, DNA, mRNA, cDNA, cRNA, etc. having a sequence are included within the meaning of "gene.”
- Such genes are single-stranded, double-stranded, or triple- or more-stranded nucleotides, aggregates of DNA strands and RNA strands, and ribonucleotides (RNA) and deoxyribonucleotides (DNA) mixed on one nucleotide strand.
- CD37 gene includes, for example, DNA, mRNA, cDNA, cRNA, etc. containing a nucleotide sequence that encodes the amino acid sequence of the CD37 protein.
- nucleotide “nucleic acid” and “nucleic acid molecule” are synonymous, and include, for example, DNA, RNA, probes, oligonucleotides, polynucleotides, primers and the like.
- Such nucleotides are single-stranded, double-stranded, or three- or more-stranded nucleotides, and are aggregates of DNA strands and RNA strands, and ribonucleotides (RNA) and deoxyribonucleotides (DNA) on one nucleotide strand.
- RNA ribonucleotides
- DNA deoxyribonucleotides
- polypeptide In the present invention, “polypeptide”, “peptide” and “protein” are synonymous.
- protein refers to “protein” from any vertebrate source, including mammals such as primates (e.g. humans and monkeys) and rodents (e.g. mice and rats). .
- antigen may be used to mean “immunogen”.
- cells include various cells derived from individual animals, subcultured cells, primary cultured cells, cell lines, recombinant cells, microorganisms, and the like.
- the "site" to which an antibody binds that is, the "site” recognized by an antibody means a partial peptide or partial conformation on an antigen that is bound or recognized by an antibody. In the present invention, such sites are also referred to as epitopes or antibody binding sites.
- the site on the CD37 protein to which the anti-CD37 antibody of the present invention binds or recognizes can be exemplified by partial peptides or partial higher-order structures on the CD37 protein.
- CDR Complementarity Determining Region
- FR Framework Region
- Heavy and light chains of antibody molecules are known to each have three CDRs.
- a CDR also called a hypervariable domain, is a site of particularly high primary structural variability within the variable regions of the heavy and light chains of an antibody. On the primary structure of , each is usually separated into three places.
- the complementarity determining region of an antibody the heavy chain complementarity determining region is denoted as CDRH1, CDRH2, and CDRH3 from the amino terminal side of the heavy chain amino acid sequence, and the light chain complementarity determining region is denoted as light chain amino acid sequence.
- CDRL1, CDRL2 and CDRL3 are designated from the amino terminal side of the sequence. These sites are sterically close to each other and determine the specificity for the binding antigen.
- the portion other than CDRH1 to CDRH3 in the heavy chain variable region amino acid sequence is called FR, and from the amino terminus to before CDRH1, from after CDRH1 to before CDRH2, from after CDRH2 to before CDRH3, and after CDRH3. to the carboxyl terminus are referred to as FRH1 through FRH4, respectively.
- portions other than CDRL1 to CDRL3 in the light chain variable region amino acid sequence are also FRs, from the amino terminus to before CDRL1, from after CDRL1 to before CDRL2, from after CDRL2 to before CDRL3, and Following CDRL3 to the carboxyl terminus are referred to as FRL1 to FRL4, respectively. That is, in the (amino acid sequences of) the variable regions of the heavy and light chains, the amino-terminal They line up continuously from the side toward the carboxyl terminus.
- antibody functional fragment means an antibody fragment that exhibits at least part of the functions of the original antibody.
- antibody functional fragments include, but are not limited to, Fab, F(ab')2, scFv, Fab', single-chain immunoglobulins, and the like.
- Such antibody functional fragments include not only those obtained by treating full-length antibody protein molecules with enzymes such as papain and pepsin, but also recombinant proteins produced in suitable host cells using recombinant genes. There may be.
- antibody functional fragments those having antigen-binding activity, that is, human CD37 are referred to as "antibody binding fragments”.
- CD37 is a four transmembrane protein belonging to the tetraspanin superfamily (Charrin S., et al., J Cell Sci. 3641-3648, 127, 2014). It is a membrane protein consisting of 281 amino acids, has both amino-terminal side and carboxyl-terminal side in cells, and can be referenced by accession numbers such as NM_001774 and NP_001765 (NCBI).
- the CD37 protein used in the present invention can be used by directly purifying from CD37-expressing cells of human or non-human mammals (rat, mouse, monkey, etc.), or by preparing a cell membrane fraction of the cells. It can also be obtained by synthesizing CD37 in vitro or producing it in a host cell by genetic engineering. Specifically, in genetic engineering, CD37 cDNA is incorporated into an expressible vector and then synthesized in a solution containing enzymes, substrates and energy substances necessary for transcription and translation, or other prokaryotic or eukaryotic The protein can be obtained by expressing CD37 by transforming an organism's host cell. It is also possible to use the genetically engineered CD37-expressing cells or cell lines expressing CD37 as the CD37 protein. Alternatively, an expression vector incorporating the CD37 cDNA can be directly administered to an immunized animal to express CD37 in the body of the immunized animal.
- CD37 also includes proteins consisting of an amino acid sequence in which one or several amino acids are substituted, deleted and/or added in the amino acid sequence of the above CD37 protein and having biological activity equivalent to that of the protein.
- "several" in this specification means 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2.
- the human CD37 protein has the amino acid sequence set forth in SEQ ID NO:18.
- the extracellular region of the human CD37 protein has an extracellular domain 1 (herein also referred to as EC1) having an amino acid sequence of positions 39 to 59 of the amino acid sequence set forth in SEQ ID NO: 18, the amino acid set forth in SEQ ID NO: 18. It is composed of extracellular domain 2 (also referred to herein as EC2) having a sequence of amino acids 112-241.
- anti-CD37 antibody both the antibody that binds to CD37 and the antibody that recognizes CD37 can be referred to as “anti-CD37 antibody” or abbreviated as “CD37 antibody”. be.
- the anti-CD37 antibody of the present invention may be derived from any species, preferably human, rat, mouse and rabbit. If derived from a species other than human, chimerization or humanization is desirable using known techniques.
- Antibodies of the present invention may be polyclonal antibodies or monoclonal antibodies, but monoclonal antibodies are preferred.
- the anti-CD37 antibody of the present invention is an antibody that can target tumor cells, that is, it has properties such as the ability to recognize tumor cells, the ability to bind to tumor cells, and the ability to be taken up and internalized within tumor cells. Therefore, the anti-CD37 antibody of the present invention and a compound having antitumor activity can be combined via a linker to form an antibody-drug conjugate.
- Antibody uptake into tumor cells is performed by (1) an assay in which a secondary antibody (fluorescently labeled) that binds to a therapeutic antibody is used to visualize the antibody uptake into cells with a fluorescence microscope (Cell Death and Differentiation (2008) 15, 751-761), (2) an assay that measures the amount of fluorescence taken up into cells using a secondary antibody (fluorescent label) that binds to a therapeutic antibody (Molecular Biology of the Cell Vol. 15, 5268-5282 , December 2004) or (3) using an immunotoxin that binds to a therapeutic antibody, a Mab-ZAP assay (Bio Techniques 28: 162-165, January 2000).
- an immunotoxin a recombinant complex protein of the catalytic domain of diphtheria toxin and protein G can also be used.
- high internalization potential refers to the survival rate of CD37-expressing cells administered with the antibody and saporin-labeled anti-rat IgG antibody (expressed as a relative rate with the cell survival rate when the antibody is not added being 100%). is preferably 70% or less, more preferably 60% or less.
- the antibody-drug conjugate of the present invention is bound to a compound that exerts an antitumor effect, it is preferable, but not essential, that the antibody itself has an antitumor effect.
- the antibody For the purpose of specifically and selectively exerting the cytotoxicity of anti-tumor compounds on tumor cells, it is important and preferable for the antibody to have the property of being internalized and transferred to tumor cells.
- An anti-CD37 antibody can be obtained by immunizing an animal with a polypeptide antigen and collecting and purifying the antibody produced in vivo using methods practiced in this field. Since it is a transmembrane protein, it is preferable to use CD37 that retains its three-dimensional structure as an antigen. Such methods include DNA immunization.
- antigens are not limited to humans, and animals can also be immunized with antigens derived from non-human animals such as mice and rats.
- antibodies applicable to human diseases can be selected by testing the cross-reactivity between the obtained antibodies that bind to heterologous antigens and human antigens.
- a monoclonal antibody can be obtained by fusing an antibody-producing cell that produces an antibody against an antigen with a myeloma cell to establish a hybridoma.
- a method for obtaining an antibody against CD37 will be specifically described below.
- An antigen can be obtained by genetically engineering a gene encoding an antigen protein to produce it in a host cell. Specifically, a vector capable of expressing an antigen gene may be prepared, introduced into a host cell to express the gene, and the expressed antigen purified. Antibodies can also be obtained by immunizing animals with the above-described genetically engineered antigen-expressing cells or antigen-expressing cell lines.
- Antibodies can also be produced by inserting the cDNA of the antigen protein into an expression vector without using the antigen protein, administering it to an animal to be immunized, expressing the antigen protein in the body of the animal, and producing an antibody against the antigen protein. can be obtained.
- (2) Production of anti-CD37 monoclonal antibody The anti-CD37 antibody used in the present invention is not particularly limited, but for example, an antibody specified by the amino acid sequence shown in the sequence listing of the present application can be preferably used. can.
- Anti-CD37 antibodies used in the present invention preferably have the following properties. (1) an antibody characterized by having the following properties; (a) specifically binds to CD37;
- the method for obtaining an antibody against CD37 of the present invention is not particularly limited as long as an anti-CD37 antibody can be obtained. Since CD37 is a transmembrane protein, CD37 retaining a higher-order structure can be used as an antigen. preferable.
- a DNA immunization method can be mentioned as an example of a preferable method for obtaining antibodies.
- the DNA immunization method is a method of inducing immunity to an antigen by transfecting an antigen-expressing plasmid into an individual animal such as a mouse or rat and expressing the antigen within the individual.
- Gene transfer methods include direct muscle injection of plasmids, intravenous injection of transfer reagents such as liposomes and polyethyleneimine, methods using viral vectors, and injection of plasmid-attached gold particles using Gene Gun. methods, such as the Hydrodynamic method, in which a large volume of plasmid solution is injected intravenously rapidly.
- a technique called in vivo electroporation is known as a technique for improving the expression level, in which electroporation is applied to the same site after intramuscular injection of the plasmid (Aihara H, Miyazaki J.; Nat Biotechnol.1998 Sep;16(9):867-70 or Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Schermana P.D. U S A. 1999 Apr 13;96(8):4262-7.).
- hybridomas can be produced by known methods, for example, by using Hybridune Hybridoma Production System (Cyto Pulse Sciences).
- CD37 cDNA is incorporated into an expression vector, and the vector is directly administered to an animal to be immunized by electroporation, gene gun, or other method, thereby expressing CD37 in the animal body to elicit an immune response.
- Administration of the vector by electroporation or the like may be performed once or multiple times, preferably multiple times, as long as it is necessary to raise the antibody titer.
- tissue e.g., lymph nodes
- myeloma preparation of myeloma cells
- cell fusion between antibody-producing cells and myeloma selection of a group of hybridomas producing the antibody of interest
- division into single cell clones cloning
- Hybridoma culture for the production of large amounts of monoclonal antibodies, or breeding of animals implanted with hybridomas.
- the resulting monoclonal antibody has high antigen specificity for CD37.
- the monoclonal antibody is not particularly limited, but an anti-CD37 mouse monoclonal antibody HH1 (Smeland E, et al., Scand J Immunol, 21(3), 205-214 (1985)) can be mentioned.
- Production of anti-CD37 antibody are repeated to separately and independently acquire monoclonal antibodies, or by other methods Even when a monoclonal antibody is separately obtained by the method, it is possible to obtain an antibody having cytotoxic activity equivalent to that of the anti-CD37 antibody obtained in step (g).
- An example of such an antibody is an antibody that binds to the same epitope as the anti-CD37 antibody obtained in step (g). If the newly prepared monoclonal antibody binds to the partial peptide or partial conformation to which the anti-CD37 antibody binds, it can be determined that the monoclonal antibody binds to the same epitope.
- the monoclonal antibody competes with the binding of the anti-CD37 antibody to CD37 (that is, the monoclonal antibody prevents the binding of the anti-CD37 antibody to CD37)
- a specific epitope can be identified. Even if the sequence or structure has not been determined, it can be determined that the monoclonal antibody binds to the same epitope as said anti-CD37. If the epitope is confirmed to be identical, it is highly expected that the monoclonal antibody has the same antigen-binding ability or biological activity as the anti-CD37 antibody.
- the antibody of the present invention includes artificially modified genes for the purpose of reducing the heteroantigen potential against humans, improving the physical properties of antibody-drug conjugates, etc.
- Recombinant antibodies such as Chimeric antibodies, Humanized antibodies, Human antibodies, etc. are also included. These antibodies can be produced using known methods.
- chimeric antibodies include antibodies in which the variable region and constant region of an antibody are different from each other, such as chimeric antibodies in which a mouse- or rat-derived antibody variable region is conjugated to a human-derived constant region (Proc. Natl. Acad. Sci USA, 81, 6851-6855, (1984)).
- Humanized antibodies include antibodies in which only CDRs are incorporated into human-derived antibodies (see Nature (1986) 321, p. 522-525), and amino acid residues of some frameworks in addition to CDR sequences by CDR transplantation. Antibodies in which groups are also grafted to human antibodies (International Publication No. 90/07861), and antibodies in which the amino acid sequences of some CDRs are modified while maintaining antigen-binding ability can be mentioned.
- humanized antibodies of the anti-CD37 murine monoclonal antibody HH1 include the light chain variable region of hmAb-L11 and the heavy chain variable region of either hmAb-H11, hmAb-H541, hmAb-H551 or hmAb-H11a. including an antibody consisting of The amino acid sequence of hmAb-L11 is shown in SEQ ID NO:2, and the amino acid sequence of hmAb-H11, hmAb-H541, hmAb-H551 or hmAb-H11a is shown in SEQ ID NO:4, 6, 8 or 10, respectively.
- the light chain variable region consists of amino acid numbers 21 to 128 of the amino acid sequence shown in SEQ ID NO: 2
- the heavy chain variable region consists of amino acid numbers 20 to 138 of the amino acid sequence shown in each SEQ ID NO. consists of the sequences shown.
- antibodies of the invention include antibodies comprising the full length light chain of hmAb-L11 and the full length heavy chain of either hmAb-H11, hmAb-H541, hmAb-H551 or hmAb-H11a.
- the light chain full-length amino acid sequence of hmAb-L11 comprises the sequence shown in amino acid numbers 21 to 234 of the amino acid sequence shown in SEQ ID NO: 2, hmAb-H11, hmAb-H541, hmAb-H551 or hmAb-H11a
- the heavy chain full-length amino acid sequence comprises the sequence shown in amino acid numbers 20-468 of the amino acid sequence shown in SEQ ID NO: 4, 6, 8 or 10, respectively.
- Specific examples include hmAb-H11L11, hmAb-H541L11, hmAb-H551L11 and hmAb-H11aL11.
- SEQ ID NO: 2 the sequence consisting of amino acid residues 44 to 54 (KASQDVSTAVD: SEQ ID NO: 19) is CDRL1, the sequence consisting of amino acid residues 70 to 76 (WASTRHT: SEQ ID NO: 20) is CDRL2, and 109 to 117.
- a sequence (RQHYSTPFT: SEQ ID NO: 21) consisting of the th amino acid residue represents CDRL3.
- the sequence consisting of 45th to 54th amino acid residues is CDRH1
- the sequence consisting of 69th to 78th amino acid residues indicates CDRH2
- the sequence consisting of amino acid residues 118 to 127 indicates CDRH3.
- the described CDR sequences are described according to the AbM definition (Handbook of Therapeutic Antibodies, Chapter 5, Bioinformatics Tools for Antibody Engineering, Andrew C. R. Martin, James Allen, 2007).
- amino acid substitutions are substitutions that occur within a group of amino acids that are related in their amino acid side chains.
- Such amino acid substitutions are preferably carried out to the extent that the properties of the substance having the original amino acid sequence are not degraded.
- antibodies that have biological activities equivalent to those of each of the above antibodies are generally 80% or more homology, preferably 85% or more homology, more preferably 90% or more homology, still more preferably 95% or more homology. Homology, most preferably 99% or more homology.
- Antibodies having biological activities equivalent to those of the above antibodies can also be selected by combining amino acid sequences in which one to several amino acid residues are substituted, deleted, or added to the amino acid sequence of the heavy or light chain. It is possible to
- the homology between two types of amino acid sequences is determined by Blast algorithm version 2.2.2 (Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David Lipman J. (1997), "Gapped BLAST and PSI-BLAST: a new generation of protein database search programs", Nucleic Acids Res. 25:3389-3402).
- the Blast algorithm is available on the Internet at www. ncbi. nlm. nih. It can also be used by accessing gov/blast.
- amino acid sequence consisting of amino acid residues 1 to 20 is a signal sequence
- amino acid sequence consisting of amino acid residues 21 to 128 is variable.
- the amino acid sequence consisting of the 129th to 234th amino acid residues is the constant region.
- sequence of SEQ ID NO:2 is set forth in FIG.
- the amino acid sequence consisting of the 1st to 19th amino acid sequences is a signal sequence
- the amino acid sequence consisting of the 20th to 138th amino acid residues is the variable region
- the amino acid sequence consisting of the 139th to 468th amino acid residues is the constant region.
- the sequences of SEQ ID NO: 3, 5, 7 or 9 are set forth in Figures 2, 3, 4 or 5.
- the antibodies of the present invention further include human antibodies that bind to CD37.
- An anti-CD37 human antibody means a human antibody that has only antibody gene sequences derived from human chromosomes.
- Anti-CD37 human antibody is produced by a method using a human antibody-producing mouse having a human chromosome fragment containing human antibody heavy chain and light chain genes (Tomizuka, K. et al., Nature Genetics (1997) 16, p. 133 -143,; Kuroiwa, Y. et al., Nucl. Acids Res.(1998) 26, p.3447-3448; Yoshida, H. et. p.69-73 (Kitagawa, Y., Matsuda, T. and Iijima, S. eds.), Kluwer Academic Publishers, 1999.; 2000) 97, p.722-727).
- Such human antibody-producing mice have disrupted endogenous immunoglobulin heavy chain and light chain loci, and instead, human immunoglobulin via a yeast artificial chromosome (YAC) vector or the like.
- Genetically modified animals into which the heavy chain and light chain loci have been introduced can be produced by producing knockout animals and transgenic animals and mating these animals.
- a recombinant human monoclonal antibody is produced by transforming a eukaryotic cell with a cDNA encoding each of the heavy and light chains of such a human antibody, preferably with a vector containing the cDNA, by gene recombination technology.
- This antibody can also be obtained from the culture supernatant by culturing the transformed cells.
- eukaryotic cells preferably CHO cells
- mammalian cells such as lymphocytes and myeloma can be used.
- phage display-derived human antibodies selected from a human antibody library (Wormstone, IM et al, Investigative Ophthalmology & Visual Science. (2002) 43 (7), p. 2301-2308; Carmen, S. et al., Briefings in Functional Genomics and Proteomics (2002), 1(2), p.189-203; 427-431, etc.) are also known.
- a phage display method (Nature Biotechnology (2005), 23, (9), p. 1105), in which the variable region of a human antibody is expressed on the surface of a phage as a single-chain antibody (scFv) and phage that binds to an antigen is selected. -1116) can be used.
- a human antibody can be obtained by constructing an expression vector having the sequence and introducing it into an appropriate host for expression (International Publication No. 92/01047). 92/20791, 93/06213, 93/11236, 93/19172, 95/01438, 95/15388, Annu.Rev.Immunol (1994) 12, p. 433-455, Nature Biotechnology (2005) 23(9), p.1105-1116).
- a newly produced human antibody binds to the partial peptide or partial conformation bound by the CD37 antibody described herein, it can be determined that the human antibody binds to the same epitope. Also confirming that the human antibody competes for the binding of the CD37 antibody described herein to CD37 (i.e., the human antibody prevents the binding of the CD37 antibody described herein to CD37). can be determined that the human antibody binds to the same epitope as the CD37 antibodies described herein, without determining the sequence or structure of the specific epitope. If the epitopes are confirmed to be identical, it is highly expected that the human antibody will have similar antigen binding capacity or biological activity to the CD37 antibodies described herein.
- the chimeric antibody, humanized antibody, or human antibody obtained by the above methods can be evaluated for antigen binding by known methods, etc., and a suitable antibody can be selected.
- DSC Differential scanning calorimetry
- Tm thermal denaturation midpoint
- Antibody storage stability is known to show some correlation with antibody thermal stability (Lori Burton, et al., Pharmaceutical Development and Technology (2007) 12, p.265-273).
- Suitable antibodies can be selected using stability as an index.
- Other criteria for selecting antibodies include high yield in suitable host cells and low aggregation in aqueous solution. For example, the antibody with the highest yield does not always exhibit the highest thermal stability, so it is necessary to make a comprehensive judgment based on the indicators described above and select the most suitable antibody for administration to humans. .
- the antibodies of the present invention also include modified antibodies.
- the modified form means an antibody obtained by chemically or biologically modifying the antibody of the present invention.
- Chemical modifications include attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and the like.
- Biological modifications include post-translational modifications (e.g., N- or O-linked glycosylation, amino- or carboxyl-terminal processing, deamidation, aspartic acid isomerization, methionine oxidation, tryptophan oxidized), and those with a methionine residue added to the amino terminus by expression in a prokaryotic host cell.
- modified antibodies of the present invention are useful for improving antibody stability and blood retention, reducing antigenicity, and detecting or isolating antibodies or antigens.
- Antibodies of the present invention also include antibodies with regulated sugar chain modifications.
- antibody production method When an antibody gene is once isolated and then introduced into an appropriate host to produce an antibody, a combination of an appropriate host and an expression vector can be used.
- antibody genes include a combination of the genes encoding the heavy chain sequences and the genes encoding the light chain sequences of the antibodies described herein.
- the heavy chain sequence gene and the light chain sequence gene can be inserted into the same expression vector, or can be inserted into separate expression vectors. be.
- animal cells When using eukaryotic cells as hosts, animal cells, plant cells, and eukaryotic microorganisms can be used.
- animal cells include mammalian cells such as monkey cells COS cells (Gluzman, Y. Cell (1981) 23, p. 175-182, ATCC CRL-1650), mouse fibroblast NIH3T3 (ATCC No. CRL-1658) and dihydrofolate reductase-deficient strains of Chinese hamster ovary cells (CHO cells, ATCC CCL-61) (Urlaub, G. and Chasin, LA Proc. Natl. Acad. Sci. US. A. (1980) 77, p.4126-4220), FreeStyle 293F cells (Invitrogen).
- COS cells Gluzman, Y. Cell (1981) 23, p. 175-182, ATCC CRL-1650
- mouse fibroblast NIH3T3 ATCC No. CRL-1658
- examples include Escherichia coli and Bacillus subtilis.
- Antibodies can be obtained by introducing the desired antibody gene into these cells by transformation and culturing the transformed cells in vitro.
- the yield may vary depending on the antibody sequence, and it is possible to select antibodies with equivalent binding activity that can be easily produced as pharmaceuticals, using the yield as an indicator. Therefore, the antibody of the present invention is characterized by comprising the steps of culturing the transformed host cell and collecting the antibody of interest or a functional fragment of the antibody from the culture obtained in the step.
- Antibodies obtained by the method for producing the antibody are also included.
- the antibody according to the present invention also includes the modified antibody and the functional fragment of the antibody, such as deletions in which one or two amino acids are deleted at the heavy chain carboxyl terminus, and amidated Such deletions (eg, heavy chains in which the proline residue at the carboxyl terminal site is amidated) are also included.
- the carboxyl-terminal deletion form of the heavy chain of the antibody according to the present invention is not limited to the above types.
- the two heavy chains constituting the antibody according to the present invention may be either one of the heavy chains selected from the group consisting of the full-length and the deletion forms, or a combination of any two can be anything.
- the quantitative ratio of each deletion product can be affected by the type and culture conditions of cultured mammalian cells that produce the antibody of the present invention. Examples include cases where one terminal amino acid residue is deleted.
- Examples of the isotype of the antibody of the present invention include IgG (IgG1, IgG2, IgG3, IgG4) and the like, preferably IgG1 or IgG2.
- Biological activities of antibodies generally include antigen-binding activity, activity of internalizing into cells expressing the antigen by binding to the antigen, activity of neutralizing antigen activity, activity of enhancing antigen activity, Antibody-dependent cellular cytotoxicity (ADCC) activity, complement-dependent cytotoxicity (CDC) activity and antibody-dependent cell-mediated phagocytosis (ADCP) can be mentioned, and the function possessed by the antibody according to the present invention is against CD37.
- a binding activity preferably an activity that internalizes into CD37-expressing cells by binding to CD37.
- the antibody of the present invention may have ADCC activity, CDC activity and/or ADCP activity in addition to cell internalization activity.
- the obtained antibody can be purified to homogeneity. Separation and purification of antibodies may be carried out using separation and purification methods commonly used for proteins. For example, by appropriately selecting and combining column chromatography, filter filtration, ultrafiltration, salting out, dialysis, preparative polyacrylamide gel electrophoresis, isoelectric focusing, etc., antibodies can be separated and purified (Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press (1996); David Lane, Cold Spring Harbor Laboratory (1988)) However, it is not limited to these.
- Chromatography includes affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, reverse phase chromatography, adsorption chromatography, and the like.
- Columns used for affinity chromatography include protein A columns and protein G columns.
- Columns used for affinity chromatography include protein A columns and protein G columns.
- Hyper D Hyper D
- POROS Sepharose F. F. (Pharmacia) and the like.
- Anti-CD37 antibody-drug conjugate (1) Drug The anti-CD37 antibody obtained in “2. can be The drug is not particularly limited as long as it has a substituent or a partial structure that can bind to the linker structure. Anti-CD37 antibody-drug conjugates can be used in a variety of applications depending on the drug to which they are attached. Examples of such drugs include substances with anti-tumor activity, substances with effect on hematologic diseases, substances with effect on autoimmune diseases, anti-inflammatory substances, anti-bacterial substances, anti-fungal substances, anti-parasitic substances, anti-inflammatory substances. Viral substances, anti-anesthetic substances and the like can be mentioned.
- antitumor compounds examples of using antitumor compounds as compounds to be bound to the anti-CD37 antibody-drug conjugate of the present invention are described below.
- the antitumor compound is not particularly limited as long as it is a compound having an antitumor effect and has a substituent or partial structure that can be bound to the linker structure.
- a part or all of the linker of the antitumor compound is cleaved in tumor cells to liberate the antitumor compound portion, thereby exerting an antitumor effect.
- the linker is cleaved at the drug-binding portion, the antitumor compound is liberated in its original structure and exerts its original antitumor effect.
- an antitumor compound for use in the present invention is the camptothecin derivative exatecan ((1S,9S)-1-amino-9-ethyl-5-fluoro-2,3-dihydro-9-hydroxy- 4-methyl-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinoline-10,13(9H,15H)-dione;
- the compound can be preferably used.
- the compound can be easily obtained, for example, by the method described in US Patent Publication No. 2016/0297890 or other known methods, and the amino group at position 1 can be suitably used as a binding site to the linker structure. .
- exatecan is sometimes released into tumor cells in a state in which a portion of the linker is bound, and even in such a state, it is a compound that exerts excellent antitumor effects.
- exatecan has a camptothecin structure
- an acidic aqueous medium for example, about pH 3
- the equilibrium is biased towards a structure with a lactone ring (closed-ring form). It is known that the equilibrium is biased toward the ring-opened structure (open-ring isomer).
- antitumor compounds include, for example, antitumor compounds described in the literature (Pharmacological Reviews, 68, p3-19, 2016), examples of which include Doxorubicin, Calicheamicin, Dorastatin ) 10, Auristatins such as monomethylauristatin E (MMAE), monomethylauristatin F (MMAF), Maytansinoids such as DM1, DM4, Pyrrolobenzodiazepine dimer SG2000 (SJG-136), camptothecin derivatives SN-38, Duocarmycins such as CC-1065, Amanitin, Daunorubicin, Mitomycin C, Bleomycin, Cytidine, Vincristine, Vinblastine, Methotrexate, Platinum system antitumor agents (cisplatin or derivatives thereof), taxol or derivatives thereof, and the like.
- MMAE monomethylauristatin E
- MMAF monomethylauristatin F
- Maytansinoids such as DM1, DM
- the number of drugs bound to one antibody molecule is an important factor that affects its efficacy and safety.
- the production of antibody-drug conjugates is carried out by specifying the reaction conditions such as the amount of raw materials and reagents to be reacted so that the number of bindings of the drug is constant. Different, usually obtained as mixtures with different numbers of drugs bound.
- the number of drug binding to one antibody molecule is specified and expressed as the mean value, ie, the average drug binding number. Unless otherwise specified in principle in the present invention, i.e., unless an antibody-drug conjugate with a specific drug binding number contained in an antibody-drug conjugate mixture with a different drug binding number is indicated, the binding number of the drug is Mean value.
- the binding number of exatecan to an antibody molecule can be controlled, and the average drug binding number per antibody can be about 1 to 10 exatecans, preferably 2 to 8, 3 to 8. , 4 to 8, 5 to 8, 6 to 8, 7 to 8, more preferably 5 to 8, still more preferably 7 to 8, even more preferably about 8 or eight.
- a person skilled in the art can design a reaction for binding a necessary number of drugs to an antibody from the description of the examples of the present application, and obtain an antibody-drug conjugate in which the binding number of exatecan is controlled. .
- the linker structure that binds the anti-CD37 antibody and the drug is not particularly limited as long as it can be used as an antibody-drug conjugate, and can be appropriately selected and used according to the purpose of use.
- An example of the linker structure includes linkers described in known literature (Pharmacol Rev 68:3-19, January 2016, Protein Cell DOI 10.1007/s13238-016-0323-0, etc.).
- Examples include VC (valine-citrulline), MC (maleimidocaproyl), SMCC (succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate: succinimidyl 4-(N- maleimidomethyl)cyclohexane-1-carboxylate), SPP (N-succinimidyl 4-(2-pyridyldithio)pentanoic acid: N-succinimidyl 4-(2-pyridyldithio)pentanoate, SS (disulfide), SPDB (4N-succinimidyl -(2-pyridyldithio)butyrate)N-succinimidyl 4-(2-pyridyldithio)butyrate, SS/hydrazone, hydrazone, carbonate.
- VC valine-citrulline
- MC maleimidocaproyl
- SMCC succ
- linker structure described in US Patent Publication 2016/0297890 (an example is described in paragraphs [0260] to [0289] of the publication), and the following structure can be preferably used.
- the left end of the structure shown below is the antibody-binding site, and the right end is the drug-binding site.
- GGFG in the linker structure below indicates an amino acid sequence linked by a peptide bond consisting of glycine-glycine-phenylalanine-glycine (GGFG).
- the 3rd position in this partial structure is the binding site for the anti-CD37 antibody.
- the 3-position binding to the antibody is characterized by the formation of a thioether.
- the 1-position nitrogen atom of this structural moiety is attached to the methylene carbon atom present in the linker containing this structure.
- the drug-linker structural portion having the following structure is preferably bound to the antibody.
- These drug-linker structural moieties may be bonded in an average number of 1 to 10 per antibody, preferably 2 to 8, more preferably 5 to 8, still more preferably 7. to 8, and even more preferably 8.
- Antibodies that can be used for the antibody-drug conjugate of the present invention have the internalization activity described in the above section "2. Production of anti-CD37 antibody” and Examples. There is no particular limitation as long as it is an anti-CD37 antibody and a functional fragment of the antibody.
- AB represents an antibody having a sulfhydryl group.
- L 1 is -(Succinimid-3-yl-N)-.
- L 1 ' represents a maleimidyl group represented by the following formula.
- -L 1 -L X has any structure represented by the formula below.
- the antibody-drug conjugate (1) is described as a structure in which one structural portion from the drug to the linker end is bound to one antibody, but this is for the sake of explanation. is a convenient description, and in practice, a plurality of such structural moieties are often bound to one antibody molecule. This situation also applies to the following description of the manufacturing method.
- compound (2) that can be obtained by a known method (for example, available by the method described in US Patent Publication No. 2016/297890 (for example, the method described in paragraphs [0336] to [0374])) ) with an antibody having a sulfhydryl group, an antibody-drug conjugate (1) can be produced.
- An antibody having a sulfhydryl group can be obtained by a method well known to those skilled in the art (Hermanson, GT, Bioconjugate Techniques, pp.56-136, pp.456-493, Academic Press (1996)).
- Traut's reagent is allowed to act on amino groups of antibodies;
- N-succinimidyl S-acetylthioalkanoates are allowed to act on amino groups of antibodies, followed by hydroxylamine;
- TCEP is used as a reducing agent in an amount of 0.3 to 3 molar equivalents per one interchain disulfide in the antibody, and reacted with the antibody in a buffer solution containing a chelating agent, thereby reducing the antibody inner chain.
- Antibodies can be obtained in which the intermediate disulfides have been partially or completely reduced.
- Chelating agents include, for example, ethylenediaminetetraacetic acid (EDTA) and diethylenetriaminepentaacetic acid (DTPA). These may be used at concentrations of 1 mM to 20 mM.
- EDTA ethylenediaminetetraacetic acid
- DTPA diethylenetriaminepentaacetic acid
- As a buffer solution sodium phosphate, sodium borate, sodium acetate solution, or the like can be used.
- antibodies can be reacted with TCEP at 4°C to 37°C for 1 to 4 hours to obtain antibodies with partially or completely reduced sulfhydryl groups.
- the drug-linker moiety can be bound via a thioether bond by carrying out a reaction that adds a sulfhydryl group to the drug-linker moiety here.
- Antibody-drug conjugates (1) with 2 to 8 drugs attached per antibody are then prepared using 2 to 20 molar equivalents of compound (2) per antibody having a sulfhydryl group.
- a solution in which compound (2) is dissolved may be added to a buffer solution containing an antibody having a sulfhydryl group for reaction.
- a sodium acetate solution, sodium phosphate, sodium borate, or the like may be used as the buffer solution.
- the pH during the reaction is 5 to 9, more preferably around pH 7.
- Organic solvents such as dimethylsulfoxide (DMSO), dimethylformamide (DMF), dimethylacetamide (DMA), and N-methyl-2-pyridone (NMP) can be used as solvents for dissolving compound (2).
- An organic solvent solution in which compound (2) is dissolved may be added to a buffer solution containing an antibody having a sulfhydryl group at 1 to 20% v/v for reaction.
- the reaction temperature is 0° C. to 37° C., more preferably 10° C. to 25° C., and the reaction time is 0.5 hours to 2 hours.
- the reaction can be terminated by quenching the reactivity of unreacted compound (2) with a thiol-containing reagent.
- Thiol-containing reagents are eg cysteine or N-acetyl-L-cysteine (NAC). More specifically, the reaction can be terminated by adding 1 to 2 molar equivalents of NAC to the compound (2) used and incubating at room temperature for 10 to 30 minutes.
- the manufactured antibody-drug conjugate (1) was subjected to concentration, buffer exchange, purification, and measurement of antibody concentration and average drug binding number per antibody molecule by the following common procedures. , the identification of the antibody-drug conjugate (1) can be performed.
- the total absorbance at a given wavelength is equal to the sum of the absorbances of all absorbing species present in the system [absorbance additivity], there is a change in the molar extinction coefficients of the antibody and the drug before and after conjugation of the antibody and the drug. Assuming that there is no antibody-drug conjugate, the antibody concentration and drug concentration in the antibody-drug conjugate are given by the following relationship.
- a Formula (2) where A 280 represents the absorbance of the aqueous antibody-drug conjugate solution at 280 nm , A 370 represents the absorbance of the aqueous antibody-drug conjugate solution at 370 nm, A A,280 represents the absorbance of the antibody at 280 nm, and A A ,370 is the absorbance of the antibody at 370 nm, AD ,280 is the absorbance of the conjugate precursor at 280 nm, AD, 370 is the absorbance of the conjugate precursor at 370 nm, and ⁇ A,280 is the absorbance of the conjugate precursor at 280 nm.
- ⁇ A,370 is the molar extinction coefficient of the antibody at 370 nm
- ⁇ D,280 is the molar extinction coefficient of the conjugate precursor at 280 nm
- ⁇ D,370 is the molar extinction coefficient of the conjugate at 370 nm. Molar extinction coefficients of the precursors are shown, C A is the antibody concentration in the antibody-drug conjugate, and CD is the drug concentration in the antibody-drug conjugate.
- ⁇ A,280, ⁇ A,370, ⁇ D,280, and ⁇ D,370 values prepared in advance (calculated estimated values or measured values obtained from UV measurement of compounds) are used.
- ⁇ A,280 can be estimated from the amino acid sequence of an antibody by a known calculation method (Protein Science, 1995, vol.4, 2411-2423).
- ⁇ A, 370 is typically zero.
- C A and C D can be determined by measuring the A 280 and A 370 of the aqueous antibody-drug conjugate solution, substituting these values into equations (1) and (2) and solving the simultaneous equations. Further, by dividing CD by CA , the average number of drug binding per antibody can be obtained.
- HPLC analysis is performed under the following measurement conditions.
- HPLC system Agilent 1290 HPLC system (Agilent Technologies) Detector: UV absorbance meter (measurement wavelength: 280 nm)
- Mobile phase A aqueous solution containing 0.10% trifluoroacetic acid (TFA), 15% 2-propanol
- Mobile phase B acetonitrile solution containing 0.075% TFA, 15% 2-propanol
- Gradient program 14%-36% (0 min-15 min), 36%-80% (15 min-17 min), 80%-14% (17 min-17.01 min), 14% (17.01 min-25 min)
- Sample injection volume 10 ⁇ L F-3.
- Drug-bound light chains i drug-bound light chains: L i
- a heavy chain a heavy chain bound with i drugs: H i
- H3 is eluted in order.
- Detection peaks can be assigned to any of L0, L1, H0, H1, H2, H3 by retention time comparison with L0 and H0.
- the drug binding numbers can be defined by those skilled in the art, but are preferably L0, L1, H0, H1, H2, H3.
- the peak area value is corrected according to the following formula using the molar extinction coefficients of the light chain, heavy chain and drug linker according to the number of bonds of the drug linker.
- the molar extinction coefficient (280 nm) of the light chain and heavy chain in each antibody is determined by a known calculation method (Protein Science, 1995, vol.4, 2411-2423), amino acids of the light chain and heavy chain of each antibody Values inferred from arrays can be used.
- H01L02 according to its amino acid sequence, a light chain molar extinction coefficient of 31710 and a heavy chain molar extinction coefficient of 79990 were used as estimates.
- the measured molar extinction coefficient (280 nm) of the compound obtained by reacting each drug linker with mercaptoethanol or N-acetylcysteine to convert the maleimide group to succinimide thioether is used. board.
- the wavelength for measuring absorbance can be appropriately set by those skilled in the art, but is preferably a wavelength at which the peak of the antibody can be measured, more preferably 280 nm.
- F-3-3 Calculate the peak area ratio (%) of each chain to the total peak area correction value according to the following formula.
- F-3-4 Calculate the average number of drug binding per antibody molecule in the antibody-drug conjugate according to the following formula.
- Drug average binding number (L 0 peak area ratio x 0 + L 1 peak area ratio x 1 + H 0 peak area ratio x 0 + H 1 peak area ratio x 1 + H 2 peak area ratio x 2 + H 3 peak area ratio x 3)/100 x 2
- a plurality of antibody-drug conjugates having approximately the same average number of drug bindings (for example, about ⁇ 1) prepared under the same conditions were mixed. It can be made into a new lot. In that case, the drug average binding number falls between the drug average binding numbers before mixing.
- antibody-drug conjugate of the present invention is the following formula:
- AB indicates the anti-CD37 antibody disclosed herein, attached to the binding linker via the antibody-derived sulfhydryl group.
- n is synonymous with the so-called DAR (Drug-to-Antibody Ratio) and indicates the drug-antibody ratio per antibody. That is, the number of drug binding to one antibody molecule is shown, which is a numerical value specified and expressed as an average value, ie, the average drug binding number.
- n may be from 2 to 8, preferably from 5 to 8, more preferably from 7 to 8, and even more preferably 8.
- the antibody represented by AB is any selected from the group consisting of the following (a) to (e)
- Antibody-drug conjugates or pharmacologically acceptable salts thereof comprising the heavy and light chain antibodies or functional fragments thereof according to 1 can include: (a) A light chain consisting of the 21st to 234th amino acid sequences of the full-length light chain amino acid sequence shown in SEQ ID NO: 2 and a heavy chain consisting of the 20th to 468th amino acid sequences of the full-length heavy chain amino acid sequence shown in SEQ ID NO: 4 an antibody consisting of; (b) a light chain consisting of the 21st to 234th amino acid sequences of the full-length light chain amino acid sequence shown in SEQ ID NO: 2 and a heavy chain consisting of the 20th to 468th amino acid sequences of the full-length heavy chain amino acid sequence shown in SEQ ID NO: 6 an antibody consisting of; (c)
- B-cell non-Hodgkin's lymphoma such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), limbic lymphoma (MZL) ), Burkitt's lymphoma (BL), or chronic lymphocytic leukemia (CLL), T-cell lymphomas (TCL) such as peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL), and myelodysplastic syndrome (MDS) can be used as a therapeutic agent for acute myeloid leukemia (AML).
- AML acute myeloid leukemia
- anti-CD37 antibody of the present invention and its functional fragment have internalization activity, they can be used as an antibody for antibody-drug conjugates.
- anti-CD37 antibody-drug conjugates of the present invention described in the above section "3.
- Anti-CD37 antibody-drug conjugate” and Examples a drug having anti-tumor activity such as cytotoxic activity is used as the drug.
- the anti-CD37 antibody-drug conjugate of the present invention When the anti-CD37 antibody-drug conjugate of the present invention is left in the air or subjected to recrystallization or purification, it absorbs water or adheres to adsorbed water, resulting in a hydrate. Such water-containing compounds or pharmacologically acceptable salts are also included in the present invention.
- acid addition salts include, for example, hydrohalides such as hydrofluorides, hydrochlorides, hydrobromides, hydroiodes; nitrates, perchlorates, sulfates, phosphates; inorganic acid salts such as; lower alkanesulfonates such as methanesulfonate, trifluoromethanesulfonate and ethanesulfonate; arylsulfonates such as benzenesulfonate and p-toluenesulfonate; formates organic acid salts such as , acetate, trifluoroacetate, malate, fumarate, succinate, citrate, tartrate, oxalate, maleate; or ornitinate, glutamate, asparagine Examples include amino acid salts such as acid
- the anti-CD37 antibody-drug conjugate of the present invention can optionally form a pharmacologically acceptable base addition salt.
- base addition salts include, for example, alkali metal salts such as sodium, potassium and lithium salts; alkaline earth metal salts such as calcium and magnesium salts; inorganic salts such as ammonium salts; salt, phenylglycine alkyl ester salt, ethylenediamine salt, N-methylglucamine salt, diethylamine salt, triethylamine salt, cyclohexylamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, diethanolamine salt, N-benzyl-N -(2-phenylethoxy)amine salts, piperazine salts, tetramethylammonium salts, tris(hydroxymethyl)aminomethane salts, and other organic amine salts.
- the present invention also includes anti-CD37 antibody-drug conjugates in which one or more atoms constituting the antibody-drug conjugate are substituted with isotopes of those atoms.
- isotopes There are two types of isotopes: radioactive isotopes and stable isotopes. Examples of isotopes include hydrogen isotopes (2H and 3H), carbon isotopes (11C, 13C and 14C), nitrogen (13N and 15N), isotopes of oxygen (15O, 17O and 18O), isotopes of fluorine (18F), and the like.
- compositions comprising isotopically-labeled antibody-drug conjugates are useful, eg, as therapeutic agents, prophylactic agents, research reagents, assay reagents, diagnostic agents, in vivo imaging agents, and the like.
- Isotopically labeled antibody-drug conjugates and mixtures of isotopically labeled antibody-drug conjugates in any proportion are all encompassed by the present invention.
- Isotope-labeled antibody-drug conjugates can be produced by methods known in the art, for example, by substituting isotopically-labeled raw materials for raw materials in the production method of the present invention described below. can be done.
- In vitro cell-killing activity can be measured, for example, by cell growth inhibitory activity.
- cell growth inhibitory activity for example, it is possible to culture cancer cell lines overexpressing CD37, add anti-CD37 antibody-drug conjugates at various concentrations to the culture system, and measure focal activity, colony formation, and inhibitory activity on spheroid proliferation.
- DLBCL diffuse large B-cell lymphoma
- FL follicular lymphoma
- CLL chronic lymphocytic leukemia
- DLBCL diffuse large B-cell lymphoma
- FL follicular lymphoma
- CLL chronic lymphocytic leukemia
- CLL chronic lymphocytic leukemia
- Therapeutic effect on cancer using experimental animals in vivo is, for example, administration of an anti-CD37 antibody-drug conjugate to SCID mice transplanted with tumor cell lines that highly express CD37, and changes in cancer cells.
- DLBCL diffuse large B-cell lymphoma
- FL follicular lymphoma
- MCL mantle cell lymphoma
- MZL limbic lymphoma
- B-cell lymphoma such as Burkitt's lymphoma (BL) non-Hodgkin's lymphoma (NHL) or chronic lymphocytic leukemia (CLL), peripheral T-cell lymphoma (PTCL), T-cell lymphoma (TCL) such as cutaneous T-cell lymphoma (CTCL), myelodysplastic syndrome (MDS),
- CTCL cutaneous T-cell lymphoma
- MDS myelodysplastic syndrome
- the type of cancer to which the anti-CD37 antibody-drug conjugate of the present invention is applied is not particularly limited as long as it expresses CD37 in the cancer cells to be treated.
- Cells from type B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, limbic lymphoma, Burkitt's lymphoma, or chronic lymphocytic leukemia can include, but are not limited to, so long as they express CD37.
- Examples of more preferred cancer types to which the anti-CD37 antibody-drug conjugate of the present invention is applied include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. can.
- the anti-CD37 antibody-drug conjugate of the present invention can be suitably administered to mammals, more preferably humans.
- the substance used in the pharmaceutical composition containing the anti-CD37 antibody-drug conjugate of the present invention can be appropriately selected from formulation additives and others commonly used in this field in terms of dosage and concentration. can be done.
- the anti-CD37 antibody-drug conjugate of the present invention can be administered as a pharmaceutical composition comprising one or more pharmaceutically compatible ingredients.
- the pharmaceutical compositions typically comprise one or more pharmaceutical carriers, such as sterile liquids, such as water and oils (including oils of petroleum, animal, vegetable, or synthetic origin, such as arachis oil). , soybean oil, mineral oil, sesame oil, etc.) Water is a more typical carrier when the pharmaceutical composition is administered intravenously, saline solution, and aqueous dextrose and glycerol solutions. can also be used as a liquid carrier, especially for injectable solutions.
- suitable pharmaceutical excipients are known in the art.
- the above compositions may also contain, if desired, a minor amount of a wetting agent. Alternatively, it may contain emulsifying agents, or pH buffering agents.Examples of suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by EW Martin, the formulation of which corresponds to the mode of administration.
- Methods of introduction can include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, and subcutaneous routes. Administration can be, for example, by infusion or bolus injection. In certain preferred embodiments, administration of the antibody-drug conjugate is by injection. Parenteral administration is a preferred route of administration.
- the pharmaceutical composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to humans.
- compositions for intravenous administration are solutions in sterile isotonic aqueous buffer.
- the medicament may also contain a solubilizing agent and a local anesthetic (eg, lignocaine) to relieve pain at the injection site.
- a local anesthetic eg, lignocaine
- the above ingredients are administered separately or together in unit dosage form (e.g., as a dry lyophilized powder or anhydrous concentrate in a hermetically sealed container such as an ampoule or sachet indicating the quantity of active agent).
- the drug can be dispensed, for example, in an infusion bottle containing sterile pharmaceutical grade water or saline.
- an ampoule of sterile water for injection or saline can be provided, for example, so that the components can be mixed prior to administration.
- the saline can be, for example, physiological saline. .
- compositions may be formulated as lyophilized formulations or liquid formulations with the selected composition and required purity.
- the formulation may contain appropriate formulation additives used in this field.
- Liquid preparations can also be similarly formulated as liquid preparations containing various formulation additives used in this field.
- the anti-CD37 antibody-drug conjugate contained in the pharmaceutical composition of the present invention has an affinity for the antigen of the antibody-drug conjugate, that is, dissociation to the antigen.
- Kd value the higher the affinity (lower the Kd value), the more effective the drug can be exhibited even at a small dose. Therefore, in determining the dosage of the antibody-drug conjugate, the dosage can also be set based on the state of affinity between the antibody-drug conjugate and the antigen.
- about 0.001 to 100 mg/kg may be administered once or multiple times at intervals of once every 1 to 180 days.
- 0.1 to 50 mg/kg, more preferably 0.1 to 30 mg/kg is administered once every 1 to 4 weeks, preferably once every 2 to 3 weeks, in multiple doses. Just do it.
- Example 1 Production of humanized anti-CD37 antibody
- 1)-1 Design of anti-CD37 humanized antibody 1-1 Molecular modeling of variable region of anti-CD37 antibody A method known as homology modeling (Methods in Enzymology, 203, 121-153 (1991)) was used. Registered in Protein data Bank (Nuc. Acid Res. 35, D301-D303 (2007)) with high sequence homology to the variable region using a commercially available protein structure analysis program Discovery Studio (manufactured by Dassault Systdiags) We searched for structures that are A three-dimensional model structure was created using the hit heavy chain, light chain, and interface structure between the heavy chain and the light chain as a template.
- variable region of the designed anti-CD37 humanized antibody light chain is designed with a humanized antibody light chain connected to the ⁇ chain constant region of human IgG1, hmAb- named L11.
- the full length amino acid sequence of hmAb-L11 is set forth in SEQ ID NO:2.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:2 is set forth in SEQ ID NO:1.
- hmAb-H11 of anti-CD37 human chimeric antibody heavy chain A human IgG1 ⁇ chain constant region connected to the designed anti-CD37 humanized antibody heavy chain variable region by grafting onto the human ⁇ chain subgroup 1 consensus sequence, which has the highest homology with the anti-CD37 human chimeric antibody.
- a modified antibody heavy chain was designed and named hmAb-H11.
- the full length amino acid sequence of hmAb-H11 is set forth in SEQ ID NO:4.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:4 is set forth in SEQ ID NO:3.
- the full length amino acid sequence of hmAb-H551 is set forth in SEQ ID NO:8.
- a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:8 is set forth in SEQ ID NO:7.
- the full length amino acid sequence of hmAb-H11a is set forth in SEQ ID NO:10.
- the nucleotide sequence encoding the amino acid sequence of SEQ ID NO:10 is set forth in SEQ ID NO:9.
- pCMA-LK was constructed by removing the neomycin resistance gene from pcDNA3.3/LK.
- hmAb-L11 expression vector A DNA fragment having the nucleotide sequence of the hmAb-L11 variable region shown in SEQ ID NO: 12 was synthesized (manufactured by Thermo Fisher Scientific). Using the In-Fusion HD PCR cloning kit, hmAb-L11 expression vector was constructed by inserting the synthesized DNA fragment into the site where pCMA-LK constructed in Example 1)-2-1 was cleaved with restriction enzyme BsiWI. bottom.
- Example 1 A fragment of about 3.4 kb obtained by digesting pCMA-LK constructed in -2-1 with restriction enzymes XbaI and PmeI and a DNA fragment of 1.1 kb were ligated using Ligation High (manufactured by Toyobo Co., Ltd.). ligated together to construct pCMA-G1.
- hmAb-H541 Expression Vector A DNA fragment having the nucleotide sequence of hmAb-H541 shown in SEQ ID NO: 15 was synthesized. Using the In-Fusion HD PCR cloning kit, the hmAb-H541 expression vector was created by inserting the synthesized DNA fragment into the site where the pCMA-G1 constructed in Example 1)-2-2 was cleaved with the restriction enzyme BlpI. It was constructed.
- hmAb-H551 Expression Vector A DNA fragment having the nucleotide sequence of hmAb-H551 shown in SEQ ID NO: 16 was synthesized. Using the In-Fusion HD PCR cloning kit, the hmAb-H551 expression vector was created by inserting the synthesized DNA fragment into the site where the pCMA-G1 constructed in Example 1)-2-2 was cleaved with the restriction enzyme BlpI. It was constructed.
- hmAb-H11a Expression Vector A DNA fragment having the nucleotide sequence of hmAb-H11a shown in SEQ ID NO: 17 was synthesized. Using the In-Fusion HD PCR cloning kit, the hmAb-H11a expression vector was created by inserting the synthesized DNA fragment into the site where the pCMA-G1 constructed in Example 1)-2-2 was cleaved with the restriction enzyme BlpI. It was constructed.
- FreeStyle 293F cells (manufactured by Thermo Fisher Scientific) were subcultured and cultured according to the manual. FreeStyle 293F cells in exponential growth phase were diluted with FreeStyle293 expression medium (manufactured by Thermo Fisher Scientific) to adjust to 2.0 ⁇ 10 6 cells/mL, and 600 mL of the cells were seeded in a 3 L Fernbach Erlenmeyer Flask (manufactured by CORNING). 1.8 mg of Polyethyleneimine (Polysciences) was added to 20 mL of Opti-Pro SFM medium (Thermo Fisher Scientific).
- 300 ⁇ g of heavy chain expression vector and 300 ⁇ g of light chain expression vector were then added to 20 mL of Opti-Pro SFM medium.
- the expression vector/Opti-Pro SFM mixture was added to the Polyethyleneimine/Opti-Pro SFM mixture, gently stirred, allowed to stand for 5 minutes, and then added to the FreeStyle 293F cells. After culturing with shaking at 95 rpm for 4 hours at 37° C. in an 8% CO 2 incubator, 600 mL of EX-CELL VPRO medium (manufactured by SAFC Biosciences) and 43.4 g/L of BD Recharge CD (manufactured by BD Biosciences) were added. 30 mL was added, and cultured with shaking at 95 rpm in an 8% CO 2 incubator at 37° C. for 6 days.
- the antibody-containing fraction was dialyzed using Slide-A-Lyzer Dialysis Cassette (manufactured by Thermo Fisher Scientific) to replace the buffer with PBS, and diluted 5-fold with a buffer of 5 mM sodium phosphate/50 mM MES/pH 7.0. After that, it was applied to a ceramic hydroxyapatite column (manufactured by Bio-Rad Laboratories) equilibrated with a buffer of 5 mM NaPi/50 mM MES/30 mM NaCl/pH 7.0. A linear gradient elution with sodium chloride was performed, and antibody-containing fractions were collected.
- the fraction was buffer-exchanged with HBSor (25 mM histidine/5% sorbitol, pH 6.0) by dialysis using Dialysis Cassette.
- the antibody was concentrated with VIVASPIN 20 (fractionation molecular weight UF10K, manufactured by Sartorius Stedim Biotech) to adjust the IgG concentration to 20-25 mg/mL. Finally, it was filtered with Minisart Plus (manufactured by Sartorius Stedim Biotech) to obtain a purified sample.
- hmAb-H11L11 prepared in Example 1)-2 was subjected to common procedures B (using 1.50 mL mg ⁇ 1 cm ⁇ 1 as the 280 nm extinction coefficient) and C described in Production Method 1, Prepared to 10.67 mg/mL in PBS6.0/EDTA.
- This solution (0.5 mL) was added with 1 M dipotassium hydrogen phosphate aqueous solution (Nacalai Tesque, Inc.; 0.0075 mL) and 10 mM TCEP (Tokyo Chemical Industry Co., Ltd.) aqueous solution (0.022 mL; .0 eq.) was added. After confirming that the pH of this solution was within 7.0 ⁇ 0.1, the solution was incubated at 37° C. for 2 hours to reduce the disulfide bonds between the chains of the antibody.
- hmAb-H11L11 prepared in Example 1)-2 was subjected to common procedures B (using 1.50 mL mg ⁇ 1 cm ⁇ 1 as the 280 nm extinction coefficient) and C described in Production Method 1, Prepared to 10.67 mg/mL in PBS6.0/EDTA.
- This solution (0.5 mL) was added with 1 M dipotassium hydrogen phosphate aqueous solution (Nacalai Tesque, Inc.; 0.0075 mL) and 10 mM TCEP (Tokyo Chemical Industry Co., Ltd.) aqueous solution (0.0294 mL; .0 eq.) was added. After confirming that the pH of this solution was within 7.0 ⁇ 0.1, the solution was incubated at 37° C. for 2 hours to reduce disulfide bonds in the interchain regions of the antibody.
- hmAb-H11L11 prepared in Example 1)-2 was subjected to common procedures B (using 1.50 mL mg ⁇ 1 cm ⁇ 1 as the 280 nm extinction coefficient) and C described in Production Method 1, Prepared to 10.67 mg/mL in PBS6.0/EDTA.
- This solution (8.3 mL) was added with 1 M dipotassium hydrogen phosphate aqueous solution (Nacalai Tesque, Inc.; 0.124 mL) and 10 mM TCEP (Tokyo Chemical Industry Co., Ltd.) aqueous solution (0.486 mL; .0 eq.) was added. After confirming that the pH of this solution was within 7.0 ⁇ 0.1, the solution was incubated at 37° C. for 2 hours to reduce disulfide bonds in the interchain regions of the antibody.
- Antibody reduction hmAb-H541L11 prepared in Example 1)-2 was subjected to common procedures B (using 1.50 mL mg ⁇ 1 cm ⁇ 1 as the 280 nm extinction coefficient) and C described in Production Method 1.
- This solution (8.9 mL) was added with 1 M dipotassium hydrogen phosphate aqueous solution (Nacalai Tesque, Inc.; 0.133 mL) and 10 mM TCEP (Tokyo Chemical Industry Co., Ltd.) aqueous solution (0.389 mL; .0 eq.) was added. After confirming that the pH of this solution was within 7.0 ⁇ 0.1, the solution was incubated at 37° C. for 2 hours to reduce disulfide bonds in the interchain regions of the antibody.
- hmAb-H551L11 prepared in Example 1)-2 was subjected to common procedures B (using 1.50 mL mg ⁇ 1 cm ⁇ 1 as the 280 nm extinction coefficient) and C described in Production Method 1, Prepared to 10.62 mg/mL in PBS6.0/EDTA.
- This solution (9.4 mL) was added with 1 M dipotassium hydrogen phosphate aqueous solution (Nacalai Tesque, Inc.; 0.141 mL) and 10 mM TCEP (Tokyo Chemical Industry Co., Ltd.) aqueous solution (0.411 mL; .0 eq.) was added. After confirming that the pH of this solution was within 7.0 ⁇ 0.1, the solution was incubated at 37° C. for 2 hours to reduce disulfide bonds in the interchain regions of the antibody.
- hmAb-H11aL11 prepared in Example 1)-2 was subjected to common procedures B (using 1.50 mL mg ⁇ 1 cm ⁇ 1 as the 280 nm extinction coefficient) and C described in Production Method 1, Prepared to 10.59 mg/mL in PBS6.0/EDTA.
- This solution (10.0 mL) was added with 1 M dipotassium hydrogen phosphate aqueous solution (Nacalai Tesque, Inc.; 0.150 mL) and 10 mM TCEP (Tokyo Chemical Industry Co., Ltd.) aqueous solution (0.510 mL; .0 eq.) was added. After confirming that the pH of this solution was within 7.0 ⁇ 0.1, the solution was incubated at 37° C. for 2 hours to reduce the disulfide bonds between the chains of the antibody.
- the average drug binding number was 7.5 when 10 mM TCEP aqueous solution and 6.0 equivalents per antibody molecule were used on the 5 mg scale. Therefore, when the 10 mM TCEP aqueous solution was increased to 8.0 equivalents per antibody molecule, the average drug binding number was improved to 7.7. However, in the production on a 100 mg scale, the average drug binding number was 7.4 even when 10 mM TCEP aqueous solution and 8.0 equivalents per antibody molecule were used.
- Example 3 Evaluation of recovery rate of anti-CD37 humanized antibody-drug conjugate in saline
- Anti-CD37 humanized antibody-drug conjugate dissolved in ABSor manufactured by Nacalai Tesque
- Otsuka physiological saline manufactured by Otsuka Pharmaceutical Factory
- Recovery rate (%) (recovery rate of specimens left at 4°C/recovery rate of specimens left at room temperature) x 100
- the antibody-drug conjugate containing the antibody whose amino acid sequence was designed in Example 1)-1-5 for the purpose of improving the physical properties of the anti-CD37 humanized antibody-drug conjugate was obtained in Example 1)- Recovery in saline at 4° C. was improved over antibody-drug conjugates containing antibodies whose amino acid sequences were designed in 1-4. Improved recovery at 4° C. in saline indicated that the anti-CD37 humanized antibody-drug conjugates are manageable in saline.
- hmAb-H11L11-DXd was shown to be difficult to handle in saline.
- the use of a glucose solution is considered, but the solution is known to cause glycation of antibodies (MAbs, v.9(4), 586-594, (2017)), and antibody- It may lead to decreased efficacy of the drug conjugate.
- some antibody drugs have been reported to cause protein aggregation when mixed with glucose solution, so it is desirable to have a choice of diluents.
- careful administration is required in patients with diabetes mellitus, diabetes insipidus, and renal failure due to the risk of electrolyte loss.
- hmAb-H11L11 was humanized using the human consensus sequence with the highest homology to the anti-CD37 mouse monoclonal antibody HH1 as an acceptor, and maintained antigen-binding activity. . However, considering the necessity of modification for the reasons described above, the amino acid sequence shown in Example 1)-1-5 was newly designed.
- Example 4 In vitro activity evaluation of antibody-drug conjugate
- the binding properties of the four antibody-drug conjugates prepared in Example 2 were analyzed by flow cytometry. evaluated.
- FIG. 6 the horizontal axis indicates the antibody concentration ( ⁇ g/ml), and the vertical axis indicates the antibody binding amount by MFI (mean fluorescence intensity).
- MFI mean fluorescence intensity
- FIG. 7 shows concentration-dependent cytostatic activity upon addition of each antibody-drug conjugate.
- the hmAb-IgG-DXd in the experiment an antibody-drug conjugate made from human IgG1 that recognizes an antigen unrelated to CD37, was used as a negative control.
- Antibody-drug conjugate in vivo antitumor effect 1 Anti-tumor effects of antibody-drug conjugates were evaluated using an animal model in which cells of a CD37-positive human tumor cell line were transplanted into immunodeficient mice. Five-week-old SCID mice (CB17/Icr-Prkdc[scid]/CrlCrlj, Charles River Laboratories Japan, Inc.) were acclimated for 3 days or more under SPF conditions before use in experiments. Mice were fed sterile chow (FR-2, Funabashi Farms Co., Ltd.) and were given sterile tap water (prepared with 5-15 ppm sodium hypochlorite solution).
- the major axis and minor axis of the transplanted tumor were measured with an electronic digital caliper (CD-15CX, Mitutoyo Corp.) twice a week, and the tumor volume was calculated according to the following formula.
- Tumor volume (mm 3 ) 1/2 x major axis (mm) x [minor axis (mm)] 2
- All antibody-drug conjugates were diluted with ABS buffer (10 mM-Acetate Buffer, 5% Sorbitol, pH 5.5) (NACALAI) and administered via the tail vein at the doses indicated in each example.
- ABS buffer 10 mM-Acetate Buffer, 5% Sorbitol, pH 5.5
- CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was suspended in 50% Matrigel (Corning, diluted with physiological saline), and 1 ⁇ 10 7 cells were placed on the right flank of female SCID mice. It was subcutaneously implanted (Day 0) and randomly grouped on Day 9.
- the four antibody-drug conjugates prepared in Example 2 were added at 1 mg/ kg and doses of 3 mg/kg were administered via the tail vein.
- An antibody-drug conjugate (hmAb-IgG1-DXd) made with human IgG as a negative control was similarly administered at a dose of 3 mg/kg.
- the results are shown in FIG.
- the horizontal axis indicates the number of days, the vertical axis indicates the tumor volume, and the error range indicates the SE value.
- Example 5 -2 Antitumor effect (2)
- 1 ⁇ 10 7 cells of CD37-positive diffuse large B-cell lymphoma cell line WSU-DLCL2 (DSMZ) were subcutaneously transplanted into the right flank of female SCID mice (Day 0), Grouping was performed randomly on Day11.
- the four antibody-drug conjugates prepared in Example 2 and hmAb-IgG1-DXd (negative control) were administered to the tail vein at doses of 1 mg/kg and 3 mg/kg.
- the results are shown in FIG.
- the horizontal axis indicates the number of days
- the vertical axis indicates the tumor volume
- the error range indicates the SE value.
- Example 5 -3 Antitumor effect (3)
- 5 ⁇ 10 6 cells of CD37-positive diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) were subcutaneously transplanted into the right flank of female SCID mice (Day 0 ), grouping was performed randomly on Day7.
- the four antibody-drug conjugates prepared in Example 2 and hmAb-IgG1-DXd (negative control) were administered to the tail vein at doses of 1 mg/kg and 3 mg/kg.
- the results are shown in FIG.
- the horizontal axis indicates the number of days
- the vertical axis indicates the tumor volume
- the error range indicates the SE value.
- IMGN529 was synthesized by the steps shown below.
- Naratuximab anti-CD37 antibody, IMGT/2Dstructure-DB card for INN 10239) was combined with common procedure B (using 1.531 mL mg -1 cm -1 as the 280 nm extinction coefficient) and C described in Manufacturing Method 1. was adjusted to 12.12 mg/mL in PBS 6.0/EDTA using
- Example 7 Antibody-drug conjugate in vivo antitumor effect 2
- Anti-tumor effects of antibody-drug conjugates were evaluated using an animal model in which cells of a CD37-positive human tumor cell line were transplanted into immunodeficient mice.
- 4-6 week-old SCID mice CB17/Icr-Prkdc [scid]/CrlCrlj: Charles River Japan, CB17/IcrJcl-Prkdc [scid]: Clea Japan
- SCID mice CB17/IcrJcl-Prkdc [scid]: Clea Japan
- mice were fed sterile chow (FR-2, Funabashi Farms Co., Ltd.) and were given sterile tap water (prepared with 5-15 ppm sodium hypochlorite solution).
- the major axis and minor axis of the transplanted tumor were measured with an electronic digital caliper (CD-15CX, Mitutoyo Corp.) twice a week, and the tumor volume was calculated according to the following formula.
- Tumor volume (mm 3 ) 1/2 x major axis (mm) x [minor axis (mm)] 2
- All antibody-drug conjugates were diluted with ABS buffer (10 mM Acetate Buffer, 5% Sorbitol, pH 5.5) (NACALAI) and administered via the tail vein at the doses indicated in each example.
- a control group As a control group (vehicle group), an ABS buffer was similarly administered.
- POLIVY manufactured by Genentech
- IMGN529 As a control group, POLIVY (manufactured by Genentech), IMGN529, and RITUXAN (manufactured by Zenyaku Kogyo Co., Ltd.) were administered to the tail vein
- Ibrutinib (synthesized by a method well known to those skilled in the art)
- Venetoclax was orally administered once a day
- TREAKISYM manufactured by SymBio Pharmaceuticals Co., Ltd.
- CD37-positive human diffuse large B-cell lymphoma cell line OCI-LY7 (DSMZ) was suspended in 50% Matrigel (Corning, diluted with physiological saline), and 1 ⁇ 10 7 cells were placed on the right flank of female SCID mice. It was subcutaneously implanted (Day 0), and randomly grouped on Day 10. Each antibody-drug conjugate was administered via the tail vein on the day of grouping. The results are shown in FIG. The horizontal axis indicates the number of days, the vertical axis indicates the tumor volume, and the error range indicates the SE value.
- Example 7 -2 Antitumor effect (2)
- 1 ⁇ 10 7 cells of CD37-positive diffuse large B-cell lymphoma cell line SU-DHL-8 (ATCC) were subcutaneously transplanted into the right flank of female SCID mice (Day 0 ), grouping was performed randomly on Day8.
- Each antibody-drug conjugate was administered via the tail vein on the day of grouping.
- the results are shown in FIG.
- the horizontal axis indicates the number of days
- the vertical axis indicates the tumor volume
- the error range indicates the SE value.
- Example 7 -3 Antitumor effect (3)
- 1 ⁇ 10 7 cells of CD37-positive diffuse large B-cell lymphoma cell line NU-DUL-1 (DSMZ) were subcutaneously transplanted into the right flank of female SCID mice (Day 0 ), and grouping was performed at random on Day 14.
- Each antibody-drug conjugate was administered via the tail vein on the day of grouping.
- the results are shown in FIG.
- the horizontal axis indicates the number of days
- the vertical axis indicates the tumor volume
- the error range indicates the SE value.
- Example 7 -4 Antitumor effect (4)
- 1 ⁇ 10 7 cells of CD37-positive diffuse large B-cell lymphoma cell line SU-DHL-4 (DSMZ) were subcutaneously transplanted into the right flank of female SCID mice (Day 0 ), and grouping was performed at random on Day 16.
- Each antibody-drug conjugate was administered via the tail vein on the day of grouping.
- the results are shown in FIG. The horizontal axis indicates the number of days, the vertical axis indicates the tumor volume, and the error range indicates the SE value.
- the hmAb-H541L11-DXd 3 mg/kg administration group prepared in Example 2)-4 showed an antitumor effect equal to or greater than that of the IMGN529 10 mg/kg administration group.
- Example 7 -5 Antitumor effect (5)
- 3 ⁇ 10 6 cells of CD37-positive human chronic lymphocytic leukemia cell line JVM-3 (DSMZ) were subcutaneously transplanted into the right flank of female SCID mice (Day 0), and randomized on Day 13. grouping was carried out. Each antibody-drug conjugate was administered via the tail vein on the day of grouping.
- RITUXAN was administered through the tail vein
- Ibrutinib and Venetoclax were administered orally once a day
- TREAKISYM was administered intraperitoneally once a day for 2 days.
- the horizontal axis indicates the number of days
- the vertical axis indicates the tumor volume
- the error range indicates the SE value.
- Example 7 -6 Antitumor effect (6)
- 1 ⁇ 10 6 cells of CD37-positive human follicular lymphoma cell line DOHH-2 (DSMZ) were subcutaneously transplanted into the right flank of female SCID mice (Day 0), and randomized on Day 21. Grouping was performed. On the day of grouping, hmAb-H541L11-DXd was administered via tail vein. The results are shown in FIG. The horizontal axis indicates the number of days, the vertical axis indicates the tumor volume, and the error range indicates the SE value.
- IMGN529 while no tumor regression was observed in the negative control hmAb-IgG1-DXd administration group, in the hmAb-H541L11-DXd administration group prepared in Example 2)-4, tumor regression at 1 mg / kg and 3 mg /kg administration resulted in complete tumor regression, similar to the POLIVY administration group.
- the present invention provides an anti-CD37 antibody with internalization activity and an antibody-drug conjugate comprising the antibody.
- the antibody-drug conjugate can be used as a therapeutic drug for B-cell malignant lymphoma and the like.
- SEQ ID NO: 1 nucleotide sequence encoding hmAb-L11 light chain
- SEQ ID NO: 2 amino acid sequence of hmAb-L11 light chain
- SEQ ID NO: 3 nucleotide sequence encoding hmAb-H11 heavy chain
- SEQ ID NO: 4 hmAb-H11 heavy chain amino acid sequence
- SEQ ID NO: 5 nucleotide sequence encoding hmAb-H541 heavy chain
- SEQ ID NO: 6 amino acid sequence of hmAb-H541 heavy chain
- SEQ ID NO: 7 nucleotide sequence encoding hmAb-H551 heavy chain
- SEQ ID NO: 8 hmAb-H551 heavy chain
- SEQ ID NO: 9 nucleotide sequence encoding hmAb-H11a heavy chain
- SEQ ID NO: 10 amino acid sequence of hmAb-H11a heavy chain
- SEQ ID NO: 11 nucleotide sequence encoding light chain signal
Abstract
Description
[1] 抗CD37抗体が、次式(a)~(f):
(a)-(Succinimid-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、
(b)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、
(c)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX)、
(d)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX)、
(e)-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、及び
(f)-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、
からなる群より選択されるいずれか1の式で示される薬物-リンカー構造と結合している抗体-薬物コンジュゲート。
GGFGは、グリシン-グリシン-フェニルアラニン-グリシンからなるペプチド結合で連結しているアミノ酸配列を示し、
-(NH-DX)は、次式:
抗CD37抗体は、配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列又は配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列と90%以上の相同性であるアミノ酸配列を有する軽鎖可変領域及び配列番号4に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列又は配列番号4に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列と90%以上の相同性であるアミノ酸配列を有する重鎖可変領域を含む抗体である。)
[2] 抗CD37抗体が、以下の(g)乃至(j)からなる群より選択されるいずれか1に記載の重鎖可変領域及び軽鎖可変領域を含む抗体である[1]の抗体-薬物コンジュゲート:
(g)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号4に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;
(h)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号6に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;
(i)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号8に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;及び
(j)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号10に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域。
[3] 抗CD37抗体が、以下の(h)乃至(j)からなる群より選択されるいずれか1に記載の重鎖可変領域及び軽鎖可変領域を含む抗体である[1]又は[2]の抗体-薬物コンジュゲート:
(h)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号6に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;
(i)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号8に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;及び
(j)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号10に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域。
[4] 抗CD37抗体が、以下の(k)乃至(n)からなる群より選択されるいずれか1に記載の重鎖及び軽鎖を含む抗体である、[1]乃至[3]のいずれか1つの抗体-薬物コンジュゲート:
(k)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号4に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;
(l)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号6に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;
(m)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号8に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;及び
(n)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号10に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖。
[5] 抗CD37抗体が、以下の(l)乃至(n)からなる群より選択されるいずれか1に記載の重鎖及び軽鎖を含む抗体である、[1]乃至[4]のいずれか1つの抗体-薬物コンジュゲート:
(l)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号6に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;
(m)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号8に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;及び
(n)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号10に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖。
[6] 薬物-リンカー構造が、以下の(c)、(d)及び(e)からなる群より選択されるいずれか1の式で示される[1]乃至[5]のいずれか1つの抗体-薬物コンジュゲート:
(c)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX)、
(d)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX)、
(e)-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)。
[7] 薬物-リンカー構造が、以下の(c)又は(e)の式で示される[1]乃至[6]のいずれか1つの抗体-薬物コンジュゲート:
(c)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX)、
(e)-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)。
[8] 以下の式(式中、Aは抗体との結合位置を示す):
[9] 以下の式:
(ここで、ABは抗体を示し、nは抗体と結合している薬物-リンカー構造の1抗体あたりの平均結合数を示し、抗体とリンカーは抗体由来のスルフヒドリル基を介して結合している。)
[10] 抗体重鎖がN結合型糖鎖付加、O結合型糖鎖付加、アミノ末端のプロセッシング、カルボキシル末端のプロセッシング、脱アミド化、アスパラギン酸の異性化、メチオニンの酸化、トリプトファンの酸化、アミノ末端にメチオニン残基の付加、プロリン残基のアミド化、及びカルボキシル末端における1つ又は2つのアミノ酸欠失からなる群より選択される1又は2以上の修飾を受けている、[1]乃至[9]のいずれか1つの抗体-薬物コンジュゲート。
[11] 抗体重鎖のカルボキシル末端において1つ又は2つのアミノ酸が欠失している[10]の抗体-薬物コンジュゲート。
[12] 2本の抗体重鎖の双方のカルボキシル末端において1つのアミノ酸が欠失している[10]又は[11]の抗体-薬物コンジュゲート。
[13] 抗体重鎖のカルボキシル末端のプロリン残基が更にアミド化されている[10]乃至[12]のいずれか1つの抗体-薬物コンジュゲート。
[14] 薬物-リンカー構造の1抗体あたりの平均結合数が1から10個の範囲である[1]乃至[13]のいずれか1つの抗体-薬物コンジュゲート。
[15] 薬物-リンカー構造の1抗体あたりの平均結合数が2から8個の範囲である[1]乃至[14]のいずれか1つの抗体-薬物コンジュゲート。
[16] 薬物-リンカー構造の1抗体あたりの平均結合数が3から8個の範囲である[1]乃至[15]のいずれか1つの抗体-薬物コンジュゲート。
[17] 薬物-リンカー構造の1抗体あたりの平均結合数が7から8個の範囲である[1]乃至[16]のいずれか1つの抗体-薬物コンジュゲート。
[18] 薬物-リンカー構造の1抗体あたりの平均結合数が8である[1]乃至[17]のいずれか1つの抗体-薬物コンジュゲート。
[19] [1]乃至[18]のいずれか1つの抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物を含むことを特徴とする医薬組成物。
[20] 抗腫瘍薬であることを特徴とする、[19]の医薬組成物。
[21] 腫瘍がCD37を発現している腫瘍であることを特徴とする、[20]の医薬組成物。
[22] 腫瘍がびまん性大細胞型B細胞リンパ腫、濾胞性リンパ腫、マントル細胞リンパ腫、辺縁体リンパ腫、バーキットリンパ腫及び慢性リンパ性白血病からなる群より選択されるいずれか1の腫瘍であることを特徴とする、[20]又は[21]の医薬組成物。
[23] 腫瘍が末梢性T細胞リンパ腫、皮膚T細胞リンパ腫等のT細胞リンパ腫、骨髄異形成症候群及び急性骨髄性白血病からなる群より選択されるいずれか1の腫瘍であることを特徴とする、[20]又は[21]の医薬組成物。
[24] [1]乃至[18]のいずれか1つの抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物を個体に投与する工程を含む、腫瘍の治療方法。
[25] 腫瘍がCD37を発現している腫瘍であることを特徴とする、[24]の治療方法。
[26] 腫瘍がびまん性大細胞型B細胞リンパ腫、濾胞性リンパ腫、マントル細胞リンパ腫、辺縁体リンパ腫 、バーキットリンパ腫及び慢性リンパ性白血病からなる群より選択されるいずれか1の腫瘍であることを特徴とする、[24]又は[25]の治療方法。
[27] 腫瘍が末梢性T細胞リンパ腫、皮膚T細胞リンパ腫等のT細胞リンパ腫、骨髄異形成症候群及び急性骨髄性白血病からなる群より選択されるいずれか1の腫瘍であることを特徴とする、[24]又は[25]の治療方法。
[28] [1]乃至[18]のいずれか1つの抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物を含む腫瘍の治療剤。
[29] 腫瘍の治療のための[1]乃至[18]のいずれか1つの抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物の使用。
[30] 腫瘍を治療するための薬剤の調製のための[1]乃至[18]のいずれか1つの抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物の使用。
[31] [1]乃至[18]のいずれか1つの抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物を、0.001~100mg/kg含む生理食塩水溶液製剤。
(i)CD37に特異的に結合し、以下の(a)乃至(d)からなる群より選択されるいずれか1に記載の重鎖可変領域及び軽鎖可変領域を含む抗体又は当該抗体の機能性断片:
(a)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号4に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;
(b)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号6に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;
(c)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号8に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;及び
(d)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号10に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域。
(ii)CD37に特異的に結合し、以下の(e)乃至(h)からなる群より選択されるいずれか1に記載の重鎖及び軽鎖を含む(i)に記載の抗体又は当該抗体の機能性断片:
(e)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号4に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;
(f)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号6に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;
(g)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号8に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;及び
(h)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号10に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖。
(iii)(i)又は(ii)に記載の抗体又は当該抗体の機能性断片をコードするポリヌクレオチド。
(iv)(iii)に記載のポリヌクレオチドを含有する発現ベクター。
(v)(iv)に記載の発現ベクターにより形質転換された宿主細胞。
(vi)宿主細胞が真核細胞である(v)に記載の宿主細胞。
(vii)(v)又は(vi)に記載の宿主細胞を培養する工程、及び当該工程で得られた培養物から目的の抗体を採取する工程を含むことを特徴とする抗体又は当該抗体の機能性断片の製造方法。
(viii)(vii)に記載の製造方法により得られることを特徴とする抗体又は当該抗体の機能性断片。
(ix)N結合型糖鎖付加、O結合型糖鎖付加、アミノ末端のプロセッシング、カルボキシル末端のプロセッシング、脱アミド化、アスパラギン酸の異性化、メチオニンの酸化、トリプトファンの酸化、アミノ末端にメチオニン残基の付加、プロリン残基のアミド化、及びカルボキシル末端における1つ又は2つのアミノ酸欠失からなる群より選択される1又は2以上の修飾を含む(viii)に記載の抗体又は当該抗体の機能性断片。
(x)重鎖のカルボキシル末端において1つ又は2つのアミノ酸が欠失している(ix)に記載の抗体又は当該抗体の機能性断片。
(xi)2本の重鎖の双方でカルボキシル末端において1つのアミノ酸が欠失している(ix)又は(x)に記載の抗体又は当該抗体の機能性断片。
(xii)重鎖のカルボキシル末端のプロリン残基が更にアミド化されている(ix)乃至(xi)のいずれか1に記載の抗体又は当該抗体の機能性断片。
(xiii)(viii)乃至(xii)のいずれか1に記載の抗体又は当該抗体の機能性断片に薬物が結合している抗体-薬物コンジュゲート。
(xiv)(v)又は(vi)に記載の宿主細胞を培養する工程、当該工程で得られた培養物から目的の抗体又は当該抗体の機能性断片を採取する工程、及び当該工程で得られた抗体又は当該抗体の機能性断片と薬物-リンカー中間化合物を反応させる工程を含むことを特徴とする、抗体-薬物コンジュゲートの製造方法。
本発明において、「遺伝子」とは、タンパク質のアミノ酸をコードするヌクレオチド配列が含まれる核酸分子又はその相補鎖を意味し、例えば、タンパク質のアミノ酸をコードするヌクレオチド配列又はその配列に相補的なヌクレオチド配列を有するポリヌクレオチド、オリゴヌクレオチド、DNA、mRNA、cDNA、cRNA等は「遺伝子」の意味に含まれる。かかる遺伝子は一本鎖、二本鎖又は三本鎖以上のヌクレオチドであり、DNA鎖とRNA鎖の会合体、一本のヌクレオチド鎖上にリボヌクレオチド(RNA)とデオキシリボヌクレオチド(DNA)が混在するもの及びそのようなヌクレオチド鎖を含む二本鎖又は三本鎖以上のヌクレオチドも「遺伝子」の意味に含まれる。本発明の「CD37遺伝子」としては、例えば、CD37タンパク質のアミノ酸配列をコードするヌクレオチド配列が含まれるDNA、mRNA、cDNA、cRNA等を挙げることができる。
CD37は、テトラスパニンスーパーファミリーに属する4回膜貫通型タンパクである(Charrin S., et al., J Cell Sci. 3641-3648,127,2014)。281アミノ酸からなる膜タンパク質であり、アミノ末端側、カルボキシル末端側共に細胞内に持ち、NM_001774、NP_001765(NCBI)等のアクセッション番号により参照可能である。
MSAQESCLSL IKYFLFVFNL FFFVLGSLIF CFGIWILIDK TSFVSFVGLA FVPLQIWSKV LAISGIFTMG IALLGCVGAL KELRCLLGLY FGMLLLLFAT QITLGILIST QRAQLERSLR DVVEKTIQKY GTNPEETAAE ESWDYVQFQL RCCGWHYPQD WFQVLILRGN GSEAHRVPCS CYNLSATNDS TILDKVILPQ LSRLGHLARS RHSADICAVP AESHIYREGC AQGLQKWLHN NLISIVGICL GVGLLELGFM TLSIFLCRNL DHVYNRLARY R
https://www.uniprot.org/uniprot/P11049
(2-1)抗体
本発明においては、CD37と結合する抗体及びCD37を認識する抗体を、いずれも「抗CD37抗体」と表記するか又は「CD37抗体」と略記することがある。
以下具体的にCD37に対する抗体の取得方法を説明する。
抗原は抗原タンパク質をコードする遺伝子を遺伝子操作によって宿主細胞に産生させることによって得ることができる。具体的には、抗原遺伝子を発現可能なベクターを作製し、これを宿主細胞に導入して該遺伝子を発現させ、発現した抗原を精製すればよい。上記の遺伝子操作による抗原発現細胞、あるいは抗原を発現している細胞株を動物に免疫する方法を用いることによっても抗体を取得できる。
(2)抗CD37モノクローナル抗体の製造
本発明で使用される抗CD37抗体は、特に制限はないが、例えば、本願の配列表で示されたアミノ酸配列で特定される抗体を好適に使用することができる。本発明において使用される抗CD37抗体としては、以下の特性を有するものが望ましい。
(1)以下の特性を有することを特徴とする抗体;
(a)CD37に特異的に結合する。
(2)CD37がヒトCD37である上記(1)に記載の抗体。
(3)CD37の高次構造を認識する上記(1)又は(2)に記載の抗体。
(a)CD37のcDNAを発現ベクターに組み込み、エレクトロポレーションや遺伝子銃等の方法によって、そのベクターを直接被免疫動物に投与することによって、動物体内においてCD37を発現させることによって、免疫反応を惹起させることができる。エレクトロポレーション等によるベクターの投与は抗体価を挙げるために必要であれば、1回でも複数回でもよく、好ましくは複数回である、
(b)免疫反応を惹起された上述の動物より、抗体産生細胞を含む組織(例えばリンパ節)の採取、
(c)骨髄腫細胞(以下「ミエローマ」という)の調製、
(d)抗体産生細胞とミエローマとの細胞融合、
(e)目的とする抗体を産生するハイブリドーマ群の選別、
(f)単一細胞クローンへの分割(クローニング)、
(g)モノクローナル抗体を大量に製造するためのハイブリドーマ培養、又はハイブリドーマを移植した動物の飼育。
(h)このようにして製造されたモノクローナル抗体の生理活性(内在化活性)、及びその結合特異性の検討、あるいは標識試薬としての特性の検定
ここで用いられる抗体価の測定法としては、例えば、フローサイトメトリー又はCell-ELISA法を挙げることができるがこれらの方法に制限されない。
さらに、「2.抗CD37抗体の製造」記載の具体的なモノクローナル抗体の取得例(a)乃至(h)の工程を再度実施して別途に独立してモノクローナル抗体を取得した場合や他の方法によって別途モノクローナル抗体を取得した場合においても、(g)の工程で得られた抗CD37抗体と同等の細胞傷害活性を有する抗体を取得することが可能である。この様な抗体の一例として、(g)の工程で得られた抗CD37抗体と同一のエピトープに結合する抗体を挙げることができる。新たに作製されたモノクローナル抗体が、前記抗CD37抗体の結合する部分ペプチド又は部分立体構造に結合すれば、該モノクローナル抗体が同一のエピトープに結合すると判定することができる。また、前記抗CD37抗体のCD37に対する結合に対して該モノクローナル抗体が競合する(即ち、該モノクローナル抗体が、前記抗CD37抗体とCD37の結合を妨げる)ことを確認することによって、具体的なエピトープの配列又は構造が決定されていなくても、該モノクローナル抗体が前記抗CD37と同一のエピトープに結合すると判定することができる。エピトープが同一であると確認された場合、該モノクローナル抗体が前記抗CD37抗体と同等の抗原結合能又は生物活性を有していることが強く期待される。
本発明の抗体には、上記CD37に対するモノクローナル抗体に加え、ヒトに対する異種抗原能を低下させること、抗体-薬物コンジュゲートの物性の改善等を目的として人為的に改変した遺伝子組み換え型抗体、例えば、キメラ(Chimeric)抗体、ヒト化(Humanized)抗体、ヒト(Human)抗体等も含まれる。これらの抗体は、既知の方法を用いて製造することができる。
抗体遺伝子を一旦単離した後、適当な宿主に導入して抗体を作製する場合には、適当な宿主と発現ベクターの組み合わせを使用することができる。抗体遺伝子の具体例としては、本明細書に記載された抗体の重鎖配列をコードする遺伝子、及び軽鎖配列をコードする遺伝子を組み合わせたものを挙げることができる。宿主細胞を形質転換する際には、重鎖配列遺伝子と軽鎖配列遺伝子は、同一の発現ベクターに挿入されていることが可能であり、又別々の発現ベクターに挿入されていることも可能である。
(1)薬物
上記「2.抗CD37抗体の製造」にて取得された抗CD37抗体はリンカー構造部分を介して薬物を結合させることによって、抗CD37抗体-薬物コンジュゲートとすることができる。薬物としては、リンカー構造に結合できる置換基、部分構造を有するものであれば特に制限はない。抗CD37抗体-薬物コンジュゲートは結合する薬物に応じて種々の用途に用いることができる。そのような薬物の例としては、抗腫瘍活性を有する物質、血液疾患に対する効果を有する物質、自己免疫疾患に対する効果を有する物質、抗炎症物質、抗菌物質、抗真菌物質、抗寄生虫物質、抗ウイルス物質、抗麻酔物質等を挙げることができる。
本発明の抗CD37抗体-薬物コンジュゲートに結合される化合物として抗腫瘍性化合物を用いる例について以下に述べる。抗腫瘍性化合物としては、抗腫瘍効果を有する化合物であって、リンカー構造に結合できる置換基、部分構造を有するものであれば特に制限はない。抗腫瘍性化合物は、リンカーの一部又は全部が腫瘍細胞内で切断されて抗腫瘍性化合物部分が遊離されて抗腫瘍効果が発現される。リンカーが薬物との結合部分で切断されれば抗腫瘍性化合物が本来の構造で遊離され、その本来の抗腫瘍効果が発揮される。
本発明の抗CD37抗体-薬物コンジュゲートにおいて薬物を抗CD37抗体に結合させるリンカー構造について述べる。
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-。
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-。
さらにより好ましくは、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-。
を挙げることができる。
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX)、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX)、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)。
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX)、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX)、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)。
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX)
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)。
本発明の抗体-薬物コンジュゲートに用いることができる抗体は、上記「2.抗CD37抗体の製造」の項及び実施例に記載の内在化活性を有する抗CD37抗体及び該抗体の機能性断片であれば特に制限がない。
下記式(1)で示される抗体-薬物コンジュゲートのうち、チオエーテルを介して抗CD37抗体とリンカー構造が結合しているものは抗CD37抗体を還元してジスルフィド結合をスルヒドリル基に変換した抗体ABに対して、既知の方法によって入手しうる化合物(2)(例えば、米国特許公開公報2016/297890号に記載の方法(例えば当該公開公報の段落[0336]~[0374]に記載の方法)で入手可能)を反応させることによって製造することができる。例えば下記の方法によって製造することができる。
ここで、L1は、
-(Succinimid-3-yl-N)-の構造で示される。
L1’は次式で示される、マレイミジル基を示す。]
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-。
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-。
-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-、
-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-。
製造した抗体-薬物コンジュゲート(1)は、以下の共通操作によって濃縮、バッファー交換、精製、抗体濃度及び抗体一分子あたりの薬物平均結合数の測定を行い、抗体-薬物コンジュゲート(1)の同定を行うことができる。
Amicon Ultra(50,000 MWCO,Millipore Corporation)の容器内に抗体もしくは抗体-薬物コンジュゲート溶液を入れ、遠心機(Allegra X-15R,Beckman Coulter,Inc.)を用いた遠心操作(2000G乃至3800Gにて5乃至20分間遠心)にて、抗体もしくは抗体-薬物コンジュゲート溶液を濃縮した。
UV測定器(Nanodrop 1000,Thermo Fisher Scientific Inc.)を用いて、メーカー規定の方法に従い、抗体濃度の測定を行った。その際に、抗体ごとに異なる280nm吸光係数(1.3mLmg-1cm-1乃至1.8mLmg-1cm-1)を用いた。
Sephadex G-25担体を使用したNAP-25カラム(Cat.No.17-0852-02,GE Healthcare Japan Corporation)を、メーカー規定の方法に従い、塩化ナトリウム(50mM)及びEDTA(2mM)を含むリン酸緩衝液(50mM,pH6.0)(本明細書でPBS6.0/EDTAと称する。)にて平衡化させた。このNAP-25カラム一本につき、抗体水溶液2.5mLをのせたのち、PBS6.0/EDTA3.5mLで溶出させた画分(3.5mL)を分取した。この画分を共通操作Aによって濃縮し、共通操作Bを用いて抗体濃度の測定を行ったのちに、PBS6.0/EDTAを用いて10mg/mLに抗体濃度を調整した。
市販のSorbitol(5%)を含む酢酸緩衝液(10mM,pH5.5;本明細書でABSと称する。)のいずれかの緩衝液でNAP-25カラムを平衡化させた。このNAP-25カラムに、抗体-薬物コンジュゲート反応水溶液(約2.5mL)をのせ、メーカー規定の量の緩衝液で溶出させることで、抗体画分を分取した。この分取画分を再びNAP-25カラムにのせ緩衝液で溶出させるゲルろ過精製操作を計2乃至3回繰り返すことで、未結合の薬物リンカーや低分子化合物(トリス(2-カルボキシエチル)ホスフィン塩酸塩(TCEP),N-アセチル-L-システイン(NAC),ジメチルスルホキシド)を除いた抗体-薬物コンジュゲートを得た。
抗体-薬物コンジュゲートにおける結合薬物濃度は、抗体-薬物コンジュゲート水溶液の280nm及び370nmの二波長におけるUV吸光度を測定したのちに下記の計算を行うことで、算出することができる。
A280=AD,280+AA,280=εD,280CD+εA,280CA 式(1)
A370=AD,370+AA,370=εD,370CD+εA,370CA 式(2)
ここで、A280は280nmにおける抗体-薬物コンジュゲート水溶液の吸光度を示し、A370は370nmにおける抗体-薬物コンジュゲート水溶液の吸光度を示し、AA,280は280nmにおける抗体の吸光度を示し、AA,370は370nmにおける抗体の吸光度を示し、AD,280は280nmにおけるコンジュゲート前駆体の吸光度を示し、AD,370は370nmにおけるコンジュゲート前駆体の吸光度を示し、εA,280は280nmにおける抗体のモル吸光係数を示し、εA,370は370nmにおける抗体のモル吸光係数を示し、εD,280は280nmにおけるコンジュゲート前駆体のモル吸光係数を示し、εD,370は370nmにおけるコンジュゲート前駆体のモル吸光係数を示し、CAは抗体-薬物コンジュゲートにおける抗体濃度を示し、CDは抗体-薬物コンジュゲートにおける薬物濃度を示す。
抗体-薬物コンジュゲートにおける抗体一分子あたりの薬物平均結合数は、前述の「(4)-5 共通操作E」に加え、以下の方法を用いる高速液体クロマトグラフィー(HPLC)分析によっても求めることができる。以下に、抗体と薬物リンカーがジスルフィド結合している場合のHPLCによる薬物平均結合数の測定方法を記載する。当業者は、この方法を参照して、抗体と薬物リンカーとの結合様式に依存して適宜、HPLCにより薬物平均結合数を測定し得る。
抗体-薬物コンジュゲート溶液(約1mg/mL、60μL)をジチオトレイトール(DTT)水溶液(100mM、15μL)と混合する。混合物を37℃で30分インキュベートすることで、抗体-薬物コンジュゲートの軽鎖及び重鎖間のジスルフィド結合を切断したサンプルを、HPLC分析に用いる。
HPLC分析を、下記の測定条件にて行う。
検出器:紫外吸光度計(測定波長:280nm)
カラム:ACQUITY UPLC BEH Phenyl(2.1×50mm、1.7μm、130Å;Waters、P/N 186002884)
カラム温度:80℃
移動相A:0.10%トリフルオロ酢酸(TFA)、15%2-プロパノールを含む水溶液
移動相B:0.075%TFA、15%2-プロパノールを含むアセトニトリル溶液
グラジエントプログラム:14%-36%(0分-15分)、36%-80%(15分-17分)、80%-14%(17分―17.01分)、14%(17.01分―25分)
サンプル注入量:10μL
F-3.データ解析
F-3-1 薬物の結合していない抗体の軽鎖(L0)及び重鎖(H0)に対して、薬物の結合した軽鎖(薬物がi個結合した軽鎖:Li)及び重鎖(薬物がi個結合した重鎖:Hi)は、結合した薬物の数に比例して疎水性が増し保持時間が大きくなることから、例えば、L0、L1、H0、H1、H2、H3の順に溶出される。L0及びH0との保持時間比較により検出ピークをL0、L1、H0、H1、H2、H3のいずれかに割り当てることができる。薬物結合数は、当業者によって定義され得るが、好ましくは、L0、L1、H0、H1、H2、H3である。
なお、抗体-薬物コンジュゲートの量を確保するために、同様な条件で作製して得られた薬物平均結合数が同程度の複数の抗体-薬物コンジュゲート(例えば±1程度)を混合して新たなロットにすることができる。その場合、薬物平均結合数は混合前の薬物平均結合数の間に収まる。
(a)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号4に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖からなる抗体;
(b)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号6に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖からなる抗体;
(c)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号8に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖からなる抗体;
(d)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号10に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖からなる抗体;又は
(e)重鎖又は軽鎖がN結合型糖鎖付加、O結合型糖鎖付加、アミノ末端のプロセッシング、カルボキシル末端のプロセッシング、脱アミド化、アスパラギン酸の異性化、メチオニンの酸化、トリプトファンの酸化、アミノ末端にメチオニン残基の付加、プロリン残基のアミド化、アミノ末端グルタミンやアミノ末端グルタミン酸のピログルタミン酸化などに代表される翻訳後修飾、及びカルボキシル末端における1つ又は2つのアミノ酸欠失からなる群より選択される1又は2以上の修飾を含む、(a)~(d)からなる群より選択されるいずれか1に記載の抗体。
上記、「2.抗CD37抗体の製造」の項及び実施例に記載された本発明の抗CD37抗体及び当該抗体の機能性断片は、腫瘍細胞表面のCD37に結合し、内在化活性を有することから、医薬として、B細胞性非ホジキンリンパ腫(NHL)、例えば、びまん性大細胞型B細胞リンパ腫(DLBCL)、濾胞性リンパ腫(FL)、マントル細胞リンパ腫(MCL)、辺縁体リンパ腫(MZL)、バーキットリンパ腫(BL)、あるいは慢性リンパ性白血病(CLL)、また末梢性T細胞リンパ腫(PTCL)、皮膚T細胞リンパ腫(CTCL)等のT細胞リンパ腫(TCL)、さらには骨髄異形成症候群(MDS)、急性骨髄性白血病(AML)の治療剤として用いることができる。
1)-1 抗CD37ヒト化抗体の設計
1)-1-1 抗CD37抗体の可変領域の分子モデリング
ホモロジーモデリングとして公知の方法(Methods in Enzymology,203,121-153(1991))を利用した。市販のタンパク質立体構造解析プログラムDiscoveryStudio(ダッソー・システムズ社製)を用いて、可変領域に対して高い配列相同性を有するProtein data Bank(Nuc.Acid Res.35,D301-D303(2007))に登録されている構造を検索した。ヒットした重鎖、軽鎖及び重鎖と軽鎖の界面構造を鋳型として、三次元モデル構造を作成した。
抗CD37マウスモノクローナル抗体HH1(Smeland E, et al.,Scand J Immunol,21(3),205-214(1985))のヒト化抗体の構築を、CDRグラフティング(Proc.Natl.Acad.Sci.USA 86,10029-10033(1989))として一般的に公知な方法によって実施した。抗CD37ヒトキメラ抗体のフレームワーク領域は、KABAT et al.(Sequences of Proteins of Immunological Interest,5th Ed.Public Health Service National Institutes of Health,Bethesda,MD.(1991))において規定されるヒトκ鎖サブグループ1とヒトγ鎖サブグループ1のコンセンサス配列に、高い相同性を有することから、それらが抗CD37ヒトキメラ抗体の軽鎖と重鎖のアクセプタとしてそれぞれ選択された。また、IMGT(登録商標)(THE INTERNATIONAL IMMUNOGENETICS INFORMATION SYSTEM)において規定されるヒトγ鎖のIGHV1-2*02とIGHJ6*01を抗CD37ヒト化抗体-薬物コンジュゲートの物性の改善を目的に重鎖のアクセプタとして選択した。アクセプタ上に移入すべきドナー残基は、Queen et al.(Proc.Natl.Acad.Sci.USA 86,10029-10033(1989))によって与えられる規準等を参考に、三次元モデルを分析し、各配列に応じて独自に設計した。
設計した抗CD37ヒト化抗体軽鎖の可変領域に、ヒトIgG1のκ鎖定常領域を接続したヒト化抗体軽鎖を設計し、hmAb-L11と命名した。hmAb-L11の全長アミノ酸配列を配列番号2に記載する。配列番号2のアミノ酸配列をコードするヌクレオチド配列を配列番号1に記載する。
抗CD37ヒトキメラ抗体と相同性が最も高いヒトγ鎖サブグループ1のコンセンサス配列へのグラフティングによって、設計した抗CD37ヒト化抗体重鎖の可変領域に、ヒトIgG1のγ鎖定常領域を接続したヒト化抗体重鎖を設計し、hmAb-H11と命名した。hmAb-H11の全長アミノ酸配列を配列番号4に記載する。配列番号4のアミノ酸配列をコードするヌクレオチド配列を配列番号3に記載する。
抗CD37ヒト化抗体-薬物コンジュゲートの物性の改善を目的に設計した抗CD37ヒト化抗体重鎖の可変領域に、ヒトIgG1のγ鎖定常領域を接続したヒト化抗体重鎖をそれぞれ、hmAb-H541、hmAb-H551、hmAb-H11aと命名した。hmAb-H541の全長アミノ酸配列を配列番号6に記載する。配列番号6のアミノ酸配列をコードするヌクレオチド配列を配列番号5に記載する。hmAb-H551の全長アミノ酸配列を配列番号8に記載する。配列番号8のアミノ酸配列をコードするヌクレオチド配列を配列番号7に記載する。hmAb-H11aの全長アミノ酸配列を配列番号10に記載する。配列番号10のアミノ酸配列をコードするヌクレオチド配列を配列番号9に記載する。
1)-2-1 軽鎖発現ベクターpCMA-LKの構築
プラスミドpcDNA3.3-TOPO/LacZ(Thermo Fisher Scientific社製)を制限酵素XbaI及びPmeIで消化して得られる約5.4kbのフラグメントと、配列番号11に示すヒト軽鎖シグナル配列及びヒトκ鎖定常領域をコードするヌクレオチド配列を含むDNA断片をIn-Fusion HD PCRクローニングキット(Takra Bio USA社製)を用いて結合し、pcDNA3.3/LKを作製した。
配列番号12に示すhmAb-L11可変領域のヌクレオチド配列のDNA断片を合成した(Thermo Fisher Scientific社製)。In-Fusion HD PCRクローニングキットを用い、実施例1)-2-1で構築したpCMA-LKを制限酵素BsiWIで切断した箇所に合成したDNA断片を挿入することにより、hmAb-L11発現ベクターを構築した。
配列番号13に示す重鎖シグナル配列及びヒト重鎖G1定常領域をコードするヌクレオチド配列を含むDNA断片を合成した(ユーロフィンジェノミクス社製)。このDNA断片を制限酵素XbaI及びPmeIで切断後、アガロースゲル電気泳動により、1.1kbのDNA断片を切り出し、Wizard SV Gel and PCR Clean-Up System(Promega社製)により精製した。実施例1)-2-1で構築したpCMA-LKを制限酵素XbaI及びPmeIで消化して得られる約3.4kbのフラグメントと、1.1kbのDNA断片をLigation High(東洋紡社製)を用いて結合し、pCMA-G1を構築した。
配列番号14に示すhmAb-H11のヌクレオチド配列のDNA断片を合成した。In-Fusion HD PCRクローニングキットを用いて、実施例1)-2-2で構築したpCMA-G1を制限酵素BlpIで切断した箇所に合成したDNA断片を挿入することにより、hmAb-H11発現ベクターを構築した。
配列番号15に示すhmAb-H541のヌクレオチド配列のDNA断片を合成した。In-Fusion HD PCRクローニングキットを用いて、実施例1)-2-2で構築したpCMA-G1を制限酵素BlpIで切断した箇所に合成したDNA断片を挿入することにより、hmAb-H541発現ベクターを構築した。
配列番号16に示すhmAb-H551のヌクレオチド配列のDNA断片を合成した。In-Fusion HD PCRクローニングキットを用いて、実施例1)-2-2で構築したpCMA-G1を制限酵素BlpIで切断した箇所に合成したDNA断片を挿入することにより、hmAb-H551発現ベクターを構築した。
配列番号17に示すhmAb-H11aのヌクレオチド配列のDNA断片を合成した。In-Fusion HD PCRクローニングキットを用いて、実施例1)-2-2で構築したpCMA-G1を制限酵素BlpIで切断した箇所に合成したDNA断片を挿入することにより、hmAb-H11a発現ベクターを構築した。
hmAb-H11を重鎖とし、hmAb-L11を軽鎖とする抗CD37ヒト化抗体をhmAb-H11L11と命名した。hmAb-H541を重鎖とし、hmAb-L11を軽鎖とする抗CD37ヒト化抗体をhmAb-H541L11と命名した。hmAb-H551を重鎖とし、hmAb-L11を軽鎖とする抗CD37ヒト化抗体をhmAb-H551L11と命名した。hmAb-H11aを重鎖とし、hmAb-L11を軽鎖とする抗CD37ヒト化抗体をhmAb-H11aL11と命名した。
FreeStyle 293F細胞(Thermo Fisher Scientific社製)はマニュアルに従い、継代、培養をおこなった。対数増殖期のFreeStyle 293F細胞をFreeStyle293 expression medium (Thermo Fisher Scientific社製)で希釈して2.0×106細胞/mLに調整し、3L Fernbach Erlenmeyer Flask(CORNING社製)に600mL播種した。1.8mgのPolyethyleneimine(Polysciences社製)をOpti-Pro SFM培地(Thermo Fisher Scientific社製)20mLに添加した。次に300μgの重鎖発現ベクターと300μgの軽鎖発現ベクターを20mLのOpti-Pro SFM培地に添加した。Polyethyleneimine/Opti-Pro SFM混合液に、発現ベクター/Opti-Pro SFM混合液を加え穏やかに攪拌し、さらに5分間静置した後にFreeStyle 293F細胞に添加した。37℃、8%CO2インキュベーターで4時間、95rpmで振とう培養後に600mLのEX-CELL VPRO培地(SAFC Biosciences社製)、及び、43.4g/LのBD Recharge CD(BD Biosciences社製)を30mL添加し、37℃、8%CO2インキュベーターで6日間、95rpmで振とう培養して得られた培養上清を孔径0.2μmのボトルトップフィルター(Thermo Fisher Scientific社製)でろ過した。
実施例1)-2-3で得られた培養上清からrProtein Aアフィニティークロマトグラフィーとセラミックハイドロキシアパタイトの2段階工程で抗体を精製した。培養上清をPBSで平衡化し、MabSelectSuReが充填されたカラム(Cytiva社製)にアプライした後に、カラム容量の2倍以上のPBSでカラムを洗浄した。次に2Mアルギニン塩酸塩溶液(pH4.0)で抗体を溶出した。抗体の含まれる画分をSlide-A-Lyzer Dialysis Cassette(Thermo Fisher Scientific社製)を用いて、透析によりPBSにバッファー置換し、5mMリン酸ナトリウム/50mM MES/pH7.0のバッファーで5倍希釈した後に、5mM NaPi/50mM MES/30mM NaCl/pH7.0のバッファーで平衡化したセラミックハイドロキシアパタイトカラム(Bio-Rad Laboratories社製)にアプライした。塩化ナトリウムによる直線的濃度勾配溶出を実施し、抗体の含まれる画分を集めた。その画分をDialysis Cassetteを用いて、透析によりHBSor(25mM ヒスチジン/5% ソルビトール、pH6.0)へバッファー置換した。VIVASPIN 20(分画分子量UF10K、Sartorius Stedim Biotech社製)にて抗体を濃縮し、IgG濃度を20~25mg/mLに調整した。最後にMinisart Plus(Sartorius Stedim Biotech社製)でろ過し、精製サンプルとした。
2)-1 抗体-薬物コンジュゲートの作製(1) hmAb-H11L11-DXd
以下に示される工程によって、hmAb-H11L11-DXdを合成した。
抗体濃度:1.30mg/mL,抗体収量:4.57mg(86%),共通操作Eにて測定された抗体一分子あたりの薬物平均結合数(n):5.6;共通操作Fにて測定された抗体一分子あたりの薬物平均結合数(n):7.5。
以下に示される工程によって、hmAb-H11L11-DXdを合成した。
抗体濃度:1.34mg/mL,抗体収量:4.69mg(88%),共通操作Eにて測定された抗体一分子あたりの薬物平均結合数(n):5.9;共通操作Fにて測定された抗体一分子あたりの薬物平均結合数(n):7.7。
以下に示される工程によって、hmAb-H11L11-DXdを合成した。
抗体濃度:2.23mg/mL,抗体収量:70.29mg(80%),共通操作Eにて測定された抗体一分子あたりの薬物平均結合数(n):5.6;共通操作Fにて測定された抗体一分子あたりの薬物平均結合数(n):7.4。
以下に示される工程によって、hmAb-H541L11-DXdを合成した。
抗体濃度:2.68mg/mL,抗体収量:84.26mg(89%),共通操作Eにて測定された抗体一分子あたりの薬物平均結合数(n):5.9;共通操作Fにて測定された抗体一分子あたりの薬物平均結合数(n):7.8。
以下に示される工程によって、hmAb-H551L11-DXdを合成した。
抗体濃度:2.43mg/mL,抗体収量:85.08mg(85%),共通操作Eにて測定された抗体一分子あたりの薬物平均結合数(n):5.7;共通操作Fにて測定された抗体一分子あたりの薬物平均結合数(n):7.8。
以下に示される工程によって、hmAb-H11aL11-DXdを合成した。
抗体濃度:2.62mg/mL,抗体収量:91.57mg(86%),共通操作Eにて測定された抗体一分子あたりの薬物平均結合数(n):5.7;共通操作Fにて測定された抗体一分子あたりの薬物平均結合数(n):7.6。
20mg/mLでABSor(ナカライテスク社製)に溶解した抗CD37ヒト化抗体-薬物コンジュゲートを大塚生理食塩水(大塚製薬工場社製)で2mg/mLへ希釈し、室温又は4℃で5時間静置した。この上清10μLをProminence(島津製作所社製)によって、YMC-Pack Diol-300 SEC,30nm,S-2μm,300×4.6mm(ワイエムシィ社製)へ注入し、移動相として3×PBS、8%イソプロパノール(PBSタブレット(タカラバイオ社製)3粒を920mLの超純水に溶解し、80mLのイソプロパノールを添加した溶液)を用いて、サイズ排除クロマトグラフィーにより分析した。抗CD37ヒト化抗体-薬物コンジュゲートの回収率は以下の式で算出した。
回収率(%)=(4℃静置検体の回収率/室温静置検体の回収率)×100
表1に示すとおり、抗CD37ヒト化抗体-薬物コンジュゲートの物性改善を目的に実施例1)-1-5でアミノ酸配列を設計した抗体を含む抗体-薬物コンジュゲートは、実施例1)-1-4でアミノ酸配列を設計した抗体を含む抗体-薬物コンジュゲートよりも、4℃、生理食塩水中での回収率が向上した。4℃、生理食塩水中での回収率が向上したことにより、当該の抗CD37ヒト化抗体-薬物コンジュゲートが生理食塩水中で取り扱い可能であることが示された。一方で、hmAb-H11L11-DXdは、生理食塩水中での取り扱いが困難であることが示された。この場合、ブドウ糖液の使用が検討されるが、当該溶液は抗体の糖化の原因となることが知られており(MAbs,v.9(4),586-594,(2017))、抗体-薬物コンジュゲートの薬効低下につながる可能性がある。また、ブドウ糖液との混合によりタンパク凝集が報告されている抗体医薬品もあり、希釈液の選択肢があることは望ましい。さらにブドウ糖液を使用した場合、電解質喪失の恐れから糖尿病、尿崩症、腎不全患者で慎重投与が必要となる。hmAb-H11L11は、抗CD37マウスモノクローナル抗体HH1に最も相同性の高いヒトコンセンサス配列をアクセプタとしてヒト化し、抗原結合活性を維持していたことから、ヒト化抗体として妥当性が高いと判断し選択した。しかしながら、前述の理由より改変が必要であると考え実施例1)-1-5に示すアミノ酸配列を新たに設計した。
4)-1 ヒト化抗CD37抗体-薬物コンジュゲートの結合性評価
実施例2で作製した抗体-薬物コンジュゲート4種(クローン名はhmAb-H11L11-DXd、hmAb-H541L11-DXd、hmAb-H551L11-DXd及びhmAb-H11aL11-DXd)の結合性をフローサイトメトリー法により評価した。37℃、5% CO2の条件下で20% FBS含有IMDM培地で培養したCD37陽性ヒトびまん性大細胞型B細胞リンパ腫細胞株OCI-LY7(DSMZ)を回収し遠心した。上清を除去後、各濃度の抗体-薬物コンジュゲート4種又は陰性対照としてヒトIgGを用いて作製した抗体-薬物コンジュゲート(hmAb-IgG1-DXd)を加えて懸濁し、4℃で1時間静置した。5% FBS含有PBSで2回洗浄した後、5% FBS含有PBSで100倍に希釈したFLUORESCEIN(FITC)―AffiniPure F(ab‘)2 Fragment Goat Anti-Human IgG, Fcγ Fragment Specific(Jackson Immuno Research)を加えて懸濁し、4℃で30分間静置した。5% FBS含有PBSで2回洗浄した後、フローサイトメーター(BD LSRFortessa TM X-20、BD Bioscience社)で検出を行った。データ解析はFlowJo(TreeStar)で行った。その結果を図6に示す。図6において横軸は抗体濃度(μg/ml)、縦軸はMFI(mean fluorescence intensity)による抗体結合量を示す。図6に示す通り、ヒト化抗CD37抗体及び抗体-薬物コンジュゲートはCD37陽性ヒトびまん性大細胞型B細胞リンパ腫細胞株OCI-LY7において濃度依存的な結合量の増加が観察された。
CD37陽性ヒトびまん性大細胞型B細胞リンパ腫細胞株OCI-LY7(DSMZ)を20%FBS含有IMDM培地中5x102細胞/100μL/wellになるよう96ウェルプレートに播種し、実施例2で作製した抗体-薬物コンジュゲート4種(クローン名はhmAb-H11L11-DXd、hmAb-H541L11-DXd、hmAb-H551L11-DXd及びhmAb-H11aL11-DXd)を終濃度0.0064nMから20nMとなるように添加した。37℃、5% CO2の条件下で6日間培養後に生存細胞数をCellTiter-GloTM Luminescent Cell Viability Assay(Promega)によるATPの定量で測定し、Vehicle群を100%としたときの細胞生存率を定量化した。図7に抗体-薬物コンジュゲートを各々添加した際の濃度依存的な細胞増殖抑制活性を示す。実験におけるhmAb-IgG-DXdは、CD37とは無関係な抗原を認識するヒトIgG1から作製した抗体-薬物コンジュゲートであり、陰性コントロールとして使用した。
抗体-薬物コンジュゲートの抗腫瘍効果は、CD37陽性ヒト腫瘍細胞株の細胞を免疫不全マウスに移植した動物モデルを用いて評価した。5週齢のSCIDマウス(CB17/Icr-Prkdc[scid]/CrlCrlj、日本チャールス・リバー)を実験使用前にSPF条件化で3日間以上馴化した。マウスには滅菌した固形飼料(FR-2,Funabashi Farms Co.,Ltd)を給餌し、滅菌した水道水(5-15ppm次亜塩素酸ナトリウム溶液を添加して調製)を与えた。移植した腫瘍の長径及び短径を電子式デジタルノギス(CD-15CX,Mitutoyo Corp.)で1週間に2回測定し、以下に示す計算式により腫瘍体積を算出した。
腫瘍体積(mm3)=1/2×長径(mm)×[短径(mm)]2
抗体-薬物コンジュゲートは全てABS緩衝液(10mM-Acetate Buffer, 5% Sorbitol, pH5.5)(NACALAI)で希釈し、各実施例に示す用量にて尾静脈内投与した。また、コントロール群(Vehicle群)としてABS緩衝液を同様に投与した。1群あたり6匹のマウスを実験に用いた。
CD37陽性ヒトびまん性大細胞型B細胞リンパ腫細胞株OCI-LY7(DSMZ)を50%マトリゲル(コーニング社、生理食塩水で希釈)に懸濁し、1×107cellsを雌SCIDマウスの右側腹部に皮下移植し(Day0)、Day9に無作為に群分けを実施した。群分け実施日に、実施例2で作製した抗体-薬物コンジュゲート4種(クローン名はhmAb-H11L11-DXd、hmAb-H541L11-DXd、hmAb-H551L11-DXd及びhmAb-H11aL11-DXd)を1mg/kg、3mg/kgの用量で尾静脈内投与した。陰性対照としてヒトIgGを用いて作製した抗体-薬物コンジュゲート(hmAb-IgG1-DXd)を3mg/kgの用量で同様に投与した。結果を図8に示す。横軸は日数、縦軸は腫瘍体積、誤差範囲はSE値を示す。
実施例5)-1と同様に、CD37陽性ヒトびまん性大細胞型B細胞リンパ腫細胞株WSU-DLCL2(DSMZ)を1×107cellsで雌SCIDマウスの右側腹部に皮下移植し(Day0)、Day11に無作為に群分けを実施した。群分け実施日に、実施例2で作製した抗体-薬物コンジュゲート4種及びhmAb-IgG1-DXd(陰性対象)を1mg/kg、3mg/kgの用量で尾静脈内投与した。結果を図9に示す。横軸は日数、縦軸は腫瘍体積、誤差範囲はSE値を示す。
実施例5)-1と同様に、CD37陽性ヒトびまん性大細胞型B細胞リンパ腫細胞株SU-DHL-8(ATCC)を5×106cellsで雌SCIDマウスの右側腹部に皮下移植し(Day0)、Day7に無作為に群分けを実施した。群分け実施日に、実施例2で作製した抗体-薬物コンジュゲート4種及びhmAb-IgG1-DXd(陰性対象)を1mg/kg、3mg/kgの用量で尾静脈内投与した。結果を図10に示す。横軸は日数、縦軸は腫瘍体積、誤差範囲はSE値を示す。
以下に示される工程によって、IMGN529を合成した。
この0.4mLスケールの反応を6回繰り返し、合わせて取得した。
抗体濃度:1.29mg/mL,抗体収量:15.61mg(54%),共通操作Eにて測定された抗体一分子あたりの薬物平均結合数(n):3.6。
抗体-薬物コンジュゲートの抗腫瘍効果は、CD37陽性ヒト腫瘍細胞株の細胞を免疫不全マウスに移植した動物モデルを用いて評価した。4-6週齢のSCIDマウス(CB17/Icr-Prkdc[scid]/CrlCrlj:日本チャールス・リバー、CB17/IcrJcl-Prkdc[scid]:日本クレア)を実験使用前にSPF条件化で3日間以上馴化した。マウスには滅菌した固形飼料(FR-2,Funabashi Farms Co.,Ltd)を給餌し、滅菌した水道水(5-15ppm次亜塩素酸ナトリウム溶液を添加して調製)を与えた。移植した腫瘍の長径及び短径を電子式デジタルノギス(CD-15CX,Mitutoyo Corp.)で1週間に2回測定し、以下に示す計算式により腫瘍体積を算出した。
腫瘍体積(mm3)=1/2×長径(mm)×[短径(mm)]2
抗体-薬物コンジュゲートは全てABS緩衝液(10mM-Acetate Buffer, 5% Sorbitol, pH5.5)(NACALAI)で希釈し、各実施例に示す用量にて尾静脈内投与した。また、コントロール群(Vehicle群)としてABS緩衝液を同様に投与した。対照群として、POLIVY(Genentech社製)、IMGN529、RITUXAN(全薬工業社製)を尾静脈内投与、Ibrutinib(当業者に周知の方法で合成)、Venetoclax(当業者に周知の方法で合成)を1日1回経口投与、TREAKISYM(シンバイオ製薬社製)を1日1回2日間腹腔内投与した。1群あたり5-6匹のマウスを実験に用いた。
CD37陽性ヒトびまん性大細胞型B細胞リンパ腫細胞株OCI-LY7(DSMZ)を50%マトリゲル(コーニング社、生理食塩水で希釈)に懸濁し、1×107cellsを雌SCIDマウスの右側腹部に皮下移植し(Day0)、Day10に無作為に群分けを実施した。群分け実施日に、各抗体-薬物コンジュゲートを尾静脈内投与した。結果を図11に示す。横軸は日数、縦軸は腫瘍体積、誤差範囲はSE値を示す。
実施例7)-1と同様に、CD37陽性ヒトびまん性大細胞型B細胞リンパ腫細胞株SU-DHL-8(ATCC)を1×107cellsで雌SCIDマウスの右側腹部に皮下移植し(Day0)、Day8に無作為に群分けを実施した。群分け実施日に、各抗体-薬物コンジュゲートを尾静脈内投与した。結果を図12に示す。横軸は日数、縦軸は腫瘍体積、誤差範囲はSE値を示す。
実施例7)-1と同様に、CD37陽性ヒトびまん性大細胞型B細胞リンパ腫細胞株NU-DUL-1(DSMZ)を1×107cellsで雌SCIDマウスの右側腹部に皮下移植し(Day0)、Day14に無作為に群分けを実施した。群分け実施日に、各抗体-薬物コンジュゲートを尾静脈内投与した。結果を図13に示す。横軸は日数、縦軸は腫瘍体積、誤差範囲はSE値を示す。
実施例7)-1と同様に、CD37陽性ヒトびまん性大細胞型B細胞リンパ腫細胞株SU-DHL-4(DSMZ)を1×107cellsで雌SCIDマウスの右側腹部に皮下移植し(Day0)、Day16に無作為に群分けを実施した。群分け実施日に、各抗体-薬物コンジュゲートを尾静脈内投与した。結果を図14に示す。横軸は日数、縦軸は腫瘍体積、誤差範囲はSE値を示す。
実施例7)-1と同様に、CD37陽性ヒト慢性リンパ性白血病細胞株JVM-3(DSMZ)を3×106cellsで雌SCIDマウスの右側腹部に皮下移植し(Day0)、Day13に無作為に群分けを実施した。群分け実施日に、各抗体-薬物コンジュゲートを尾静脈内投与した。また、RITUXANを尾静脈内投与、Ibrutinib、Venetoclaxを1日1回経口投与、TREAKISYMを1日1回2日間腹腔内投与した。結果を図15に示す。横軸は日数、縦軸は腫瘍体積、誤差範囲はSE値を示す。
実施例7)-1と同様に、CD37陽性ヒト濾胞性リンパ腫細胞株DOHH-2(DSMZ)を1×106cellsで雌SCIDマウスの右側腹部に皮下移植し(Day0)、Day21に無作為に群分けを実施した。群分け実施日に、hmAb-H541L11-DXdを尾静脈内投与した。結果を図16に示す。横軸は日数、縦軸は腫瘍体積、誤差範囲はSE値を示す。
配列番号2:hmAb-L11軽鎖のアミノ酸配列
配列番号3:hmAb-H11重鎖をコードするヌクレオチド配列
配列番号4:hmAb-H11重鎖のアミノ酸配列
配列番号5:hmAb-H541重鎖をコードするヌクレオチド配列
配列番号6:hmAb-H541重鎖のアミノ酸配列
配列番号7:hmAb-H551重鎖をコードするヌクレオチド配列
配列番号8:hmAb-H551重鎖のアミノ酸配列
配列番号9:hmAb-H11a重鎖をコードするヌクレオチド配列
配列番号10:hmAb-H11a重鎖のアミノ酸配列
配列番号11:軽鎖シグナル配列及びヒトκ軽鎖定常領域をコードするヌクレオチド配列を含むヌクレオチド断片
配列番号12:hmAb-L11軽鎖の可変領域をコードするヌクレオチド配列
配列番号13:重鎖シグナル配列及びヒトG1重鎖定常領域をコードするヌクレオチド配列を含むヌクレオチド断片
配列番号14:hmAb-H11重鎖の可変領域をコードするヌクレオチド配列
配列番号15:hmAb-H541重鎖の可変領域をコードするヌクレオチド配列
配列番号16:hmAb-H551重鎖の可変領域をコードするヌクレオチド配列
配列番号17:hmAb-H11a重鎖の可変領域をコードするヌクレオチド配列
配列番号18:ヒトCD37のアミノ酸配列
配列番号19:ヒト化抗CD37抗体のCDRL1配列
配列番号20:ヒト化抗CD37抗体のCDRL2配列
配列番号21:ヒト化抗CD37抗体のCDRL3配列
配列番号22:ヒト化抗CD37抗体のCDRH1配列
配列番号23:ヒト化抗CD37抗体のCDRH2配列
配列番号24:ヒト化抗CD37抗体のCDRH3配列
Claims (31)
- 抗CD37抗体が、次式(a)~(f):
(a)-(Succinimid-3-yl-N)-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、
(b)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、
(c)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX)、
(d)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX)、
(e)-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、及び
(f)-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)、
からなる群より選択されるいずれか1の式で示される薬物-リンカー構造と結合している抗体-薬物コンジュゲート。
(ここで、-(Succinimid-3-yl-N)-は次式:
GGFGは、グリシン-グリシン-フェニルアラニン-グリシンからなるペプチド結合で連結しているアミノ酸配列を示し、
-(NH-DX)は、次式:
で示される、1位のアミノ基の窒素原子が結合部位となっている基であり、
抗CD37抗体は、配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列又は配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列と90%以上の相同性であるアミノ酸配列を有する軽鎖可変領域及び配列番号4に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列又は配列番号4に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列と90%以上の相同性であるアミノ酸配列を有する重鎖可変領域を含む抗体である。) - 抗CD37抗体が、以下の(g)乃至(j)からなる群より選択されるいずれか1に記載の重鎖可変領域及び軽鎖可変領域を含む抗体である請求項1に記載の抗体-薬物コンジュゲート:
(g)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号4に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;
(h)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号6に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;
(i)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号8に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;及び
(j)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号10に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域。 - 抗CD37抗体が、以下の(h)乃至(j)からなる群より選択されるいずれか1に記載の重鎖可変領域及び軽鎖可変領域を含む抗体である請求項1又は2に記載の抗体-薬物コンジュゲート:
(h)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号6に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;
(i)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号8に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域;及び
(j)配列番号2に示される軽鎖全長アミノ酸配列の21~128番目のアミノ酸配列からなる軽鎖可変領域及び配列番号10に示される重鎖全長アミノ酸配列の20~138番目のアミノ酸配列からなる重鎖可変領域。 - 抗CD37抗体が、以下の(k)乃至(n)からなる群より選択されるいずれか1に記載の重鎖及び軽鎖を含む抗体である、請求項1乃至3のいずれか1項に記載の抗体-薬物コンジュゲート:
(k)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号4に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;
(l)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号6に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;
(m)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号8に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;及び
(n)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号10に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖。 - 抗CD37抗体が、以下の(l)乃至(n)からなる群より選択されるいずれか1に記載の重鎖及び軽鎖を含む抗体である、請求項1乃至4のいずれか1項に記載の抗体-薬物コンジュゲート:
(l)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号6に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;
(m)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号8に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖;及び
(n)配列番号2に示される軽鎖全長アミノ酸配列の21~234番目のアミノ酸配列からなる軽鎖及び配列番号10に示される重鎖全長アミノ酸配列の20~468番目のアミノ酸配列からなる重鎖。 - 薬物-リンカー構造が、以下の(c)、(d)及び(e)からなる群より選択されるいずれか1の式で示される請求項1乃至5のいずれか1項に記載の抗体-薬物コンジュゲート:
(c)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX)、
(d)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2CH2-O-CH2-C(=O)-(NH-DX)、
(e)-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)。 - 薬物-リンカー構造が、以下の(c)又は(e)の式で示される請求項1乃至6のいずれか1項に記載の抗体-薬物コンジュゲート:
(c)-(Succinimid-3-yl-N)-CH2CH2CH2CH2CH2-C(=O)-GGFG-NH-CH2-O-CH2-C(=O)-(NH-DX)、
(e)-(Succinimid-3-yl-N)-CH2CH2-C(=O)-NH-CH2CH2O-CH2CH2O-CH2CH2-C(=O)-GGFG-NH-CH2CH2CH2-C(=O)-(NH-DX)。 - 抗体重鎖がN結合型糖鎖付加、O結合型糖鎖付加、アミノ末端のプロセッシング、カルボキシル末端のプロセッシング、脱アミド化、アスパラギン酸の異性化、メチオニンの酸化、トリプトファンの酸化、アミノ末端にメチオニン残基の付加、プロリン残基のアミド化、及びカルボキシル末端における1つ又は2つのアミノ酸欠失からなる群より選択される1又は2以上の修飾を受けている、請求項1乃至9のいずれか1項に記載の抗体-薬物コンジュゲート。
- 抗体重鎖のカルボキシル末端において1つ又は2つのアミノ酸が欠失している請求項10に記載の抗体-薬物コンジュゲート。
- 2本の抗体重鎖の双方のカルボキシル末端において1つのアミノ酸が欠失している請求項10又は請求項11に記載の抗体-薬物コンジュゲート。
- 抗体重鎖のカルボキシル末端のプロリン残基が更にアミド化されている請求項10乃至12のいずれか1項に記載の抗体-薬物コンジュゲート。
- 薬物-リンカー構造の1抗体あたりの平均結合数が1から10個の範囲である請求項1乃至13のいずれか1項に記載の抗体-薬物コンジュゲート。
- 薬物-リンカー構造の1抗体あたりの平均結合数が2から8個の範囲である請求項1乃至14のいずれか1項に記載の抗体-薬物コンジュゲート。
- 薬物-リンカー構造の1抗体あたりの平均結合数が3から8個の範囲である請求項1乃至15のいずれか1項に記載の抗体-薬物コンジュゲート。
- 薬物-リンカー構造の1抗体あたりの平均結合数が7から8個の範囲である請求項1乃至16のいずれか1項に記載の抗体-薬物コンジュゲート。
- 薬物-リンカー構造の1抗体あたりの平均結合数が8である請求項1乃至17のいずれか1項に記載の抗体-薬物コンジュゲート。
- 請求項1乃至18のいずれか1項に記載の抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物を含むことを特徴とする医薬組成物。
- 抗腫瘍薬であることを特徴とする、請求項19に記載の医薬組成物。
- 腫瘍がCD37を発現している腫瘍であることを特徴とする、請求項20に記載の医薬組成物。
- 腫瘍がびまん性大細胞型B細胞リンパ腫、濾胞性リンパ腫、マントル細胞リンパ腫、辺縁体リンパ腫、バーキットリンパ腫及び慢性リンパ性白血病からなる群より選択されるいずれか1の腫瘍であることを特徴とする、請求項20又は21に記載の医薬組成物。
- 腫瘍が末梢性T細胞リンパ腫、皮膚T細胞リンパ腫等のT細胞リンパ腫、骨髄異形成症候群及び急性骨髄性白血病からなる群より選択されるいずれか1の腫瘍であることを特徴とする、請求項20又は21に記載の医薬組成物。
- 請求項1乃至18のいずれか1項に記載の抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物を個体に投与する工程を含む、腫瘍の治療方法。
- 腫瘍がCD37を発現している腫瘍であることを特徴とする、請求項24に記載の治療方法。
- 腫瘍がびまん性大細胞型B細胞リンパ腫、濾胞性リンパ腫、マントル細胞リンパ腫、辺縁体リンパ腫 、バーキットリンパ腫及び慢性リンパ性白血病からなる群より選択されるいずれか1の腫瘍であることを特徴とする、請求項24又は25に記載の治療方法。
- 腫瘍が末梢性T細胞リンパ腫、皮膚T細胞リンパ腫等のT細胞リンパ腫、骨髄異形成症候群及び急性骨髄性白血病からなる群より選択されるいずれか1の腫瘍であることを特徴とする、請求項24又は25に記載の治療方法。
- 請求項1乃至18のいずれか1項に記載の抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物を含む腫瘍の治療剤。
- 腫瘍の治療のための請求項1乃至18のいずれか1項に記載の抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物の使用。
- 腫瘍を治療するための薬剤の調製のための請求項1乃至18のいずれか1項に記載の抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物の使用。
- 請求項1乃至18のいずれか1項に記載の抗体-薬物コンジュゲート、その薬理学的に許容され得る塩、又はそれらの水和物を、0.001~100mg/kg含む生理食塩水溶液製剤。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3235358A CA3235358A1 (en) | 2021-10-18 | 2022-10-17 | Anti-cd37 antibody-drug conjugate |
AU2022368385A AU2022368385A1 (en) | 2021-10-18 | 2022-10-17 | Anti-cd37 antibody-drug conjugate |
CONC2024/0003299A CO2024003299A2 (es) | 2021-10-18 | 2024-03-18 | Conjugado anticuerpo-fármaco anti-cd37 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021-170114 | 2021-10-18 | ||
JP2021170114 | 2021-10-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023068226A1 true WO2023068226A1 (ja) | 2023-04-27 |
Family
ID=86059233
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2022/038604 WO2023068226A1 (ja) | 2021-10-18 | 2022-10-17 | 抗cd37抗体-薬物コンジュゲート |
Country Status (5)
Country | Link |
---|---|
AU (1) | AU2022368385A1 (ja) |
CA (1) | CA3235358A1 (ja) |
CO (1) | CO2024003299A2 (ja) |
TW (1) | TW202330041A (ja) |
WO (1) | WO2023068226A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117264072A (zh) * | 2023-11-22 | 2023-12-22 | 江苏迈威康新药研发有限公司 | 一种抗sn38单抗及其应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009502171A (ja) * | 2005-07-25 | 2009-01-29 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Cd37特異的及びcd20特異的結合分子を用いたb細胞の減少 |
JP2010535483A (ja) * | 2007-08-09 | 2010-11-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗cd37抗体 |
JP2014515742A (ja) * | 2011-04-01 | 2014-07-03 | イミュノジェン, インコーポレイテッド | Cd37結合性分子及びその免疫複合体 |
JP2015501654A (ja) * | 2011-12-13 | 2015-01-19 | ノルディック ナノベクター アーエス | 治療用キメラ型抗cd37抗体hh1 |
JP2016532688A (ja) * | 2013-08-01 | 2016-10-20 | アジェンシス,インコーポレイテッド | Cd37タンパク質に結合する抗体薬物結合体(adc) |
WO2017002776A1 (ja) * | 2015-06-29 | 2017-01-05 | 第一三共株式会社 | 抗体-薬物コンジュゲートの選択的製造方法 |
WO2020022363A1 (ja) * | 2018-07-25 | 2020-01-30 | 第一三共株式会社 | 抗体-薬物コンジュゲートの効果的な製造方法 |
-
2022
- 2022-10-17 TW TW111139216A patent/TW202330041A/zh unknown
- 2022-10-17 WO PCT/JP2022/038604 patent/WO2023068226A1/ja active Application Filing
- 2022-10-17 CA CA3235358A patent/CA3235358A1/en active Pending
- 2022-10-17 AU AU2022368385A patent/AU2022368385A1/en active Pending
-
2024
- 2024-03-18 CO CONC2024/0003299A patent/CO2024003299A2/es unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009502171A (ja) * | 2005-07-25 | 2009-01-29 | トゥルビオン・ファーマシューティカルズ・インコーポレーテッド | Cd37特異的及びcd20特異的結合分子を用いたb細胞の減少 |
JP2010535483A (ja) * | 2007-08-09 | 2010-11-25 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗cd37抗体 |
JP2014515742A (ja) * | 2011-04-01 | 2014-07-03 | イミュノジェン, インコーポレイテッド | Cd37結合性分子及びその免疫複合体 |
JP2015501654A (ja) * | 2011-12-13 | 2015-01-19 | ノルディック ナノベクター アーエス | 治療用キメラ型抗cd37抗体hh1 |
JP2016532688A (ja) * | 2013-08-01 | 2016-10-20 | アジェンシス,インコーポレイテッド | Cd37タンパク質に結合する抗体薬物結合体(adc) |
WO2017002776A1 (ja) * | 2015-06-29 | 2017-01-05 | 第一三共株式会社 | 抗体-薬物コンジュゲートの選択的製造方法 |
WO2020022363A1 (ja) * | 2018-07-25 | 2020-01-30 | 第一三共株式会社 | 抗体-薬物コンジュゲートの効果的な製造方法 |
Non-Patent Citations (2)
Title |
---|
ARROYO-OLARTE RUBEN D., BRAVO RODRÍGUEZ RICARDO, MORALES-RÍOS EDGAR: "Genome Editing in Bacteria: CRISPR-Cas and Beyond", MICROORGANISMS, vol. 9, no. 4, pages 844, XP093058119, DOI: 10.3390/microorganisms9040844 * |
TOSHINORI AGATSUMA: "Development of New ADC Technology with Topoisomerase I Inhibitor", THE PHARMACEUTICAL SOCIETY OF JAPAN, vol. 137, no. 5, 1 January 2017 (2017-01-01), pages 545 - 550, XP055698408, DOI: 10.1248/yakushi.16-00255-4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117264072A (zh) * | 2023-11-22 | 2023-12-22 | 江苏迈威康新药研发有限公司 | 一种抗sn38单抗及其应用 |
CN117264072B (zh) * | 2023-11-22 | 2024-03-22 | 江苏迈威康新药研发有限公司 | 一种抗sn38单抗及其应用 |
Also Published As
Publication number | Publication date |
---|---|
AU2022368385A1 (en) | 2024-04-11 |
CO2024003299A2 (es) | 2024-04-08 |
TW202330041A (zh) | 2023-08-01 |
CA3235358A1 (en) | 2023-04-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11077202B2 (en) | Anti-CDH6 antibody and anti-CDH6 antibody-drug conjugate | |
US10906974B2 (en) | Anti-GPR20 antibody and anti-GPR20 antibody-drug conjugate | |
JP6770535B2 (ja) | Cd123抗体及びその複合体 | |
WO2023068226A1 (ja) | 抗cd37抗体-薬物コンジュゲート | |
WO2023042097A1 (en) | Antibody-drug conjugate for use in methods of treating chemotherapy-resistant cancer | |
US20240115721A1 (en) | Anti-dll3 antibody-drug conjugate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22883530 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022368385 Country of ref document: AU Ref document number: AU2022368385 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 809665 Country of ref document: NZ |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024006135 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2401002322 Country of ref document: TH |
|
ENP | Entry into the national phase |
Ref document number: 2022368385 Country of ref document: AU Date of ref document: 20221017 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 3235358 Country of ref document: CA |